Urinary system disorder
MONDO:0002118A disease involving the renal system.
Also known as: disease of renal system, disease or disorder of renal system, disease, urinary tract, disease, urologic, disease, urological, diseases, urinary tract, diseases, urologic, diseases, urological
4758 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 915 trials in this tab.
-
Kidney cancer vaccine trial pulled before it began
⭐️ VACCINE ⭐️ TerminatedThis early-phase study aimed to test a new vaccine called KSD-201 in people with advanced clear cell renal cell carcinoma whose cancer had stopped responding to standard treatments. The vaccine uses the patient's own immune cells to try to fight the cancer. However, the trial was…
Phase: EARLY_PHASE1 • Sponsor: Kousai Bio Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:30 UTC
-
Can the HPV vaccine protect transplant patients? new study investigates
⭐️ VACCINE ⭐️ OngoingThis study looks at how well the HPV9 vaccine (Gardasil 9) works in people who have had a kidney transplant. Researchers will measure antibody levels in 30 transplant recipients over 24 months and compare them to published data from healthy individuals. The goal is to see if the …
Phase: PHASE4 • Sponsor: Medical College of Wisconsin • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
New combo therapy shows promise for tough kidney cancer
Disease control OngoingThis study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental drug tazemetostat offered to patients with rare, aggressive tumors
Disease control NO_LONGER_AVAILABLEThis expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy after bladder cancer surgery: could it keep the cancer away?
Disease control OngoingThis Phase 3 trial tests whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent bladder cancer from returning after surgery. About 739 patients with muscle-invasive or locally advanced urothelial cancer are randomly assigned to receive pembrolizumab or just be o…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New virus therapy aims to keep bladder cancer from returning
Disease control OngoingThis early-stage trial tests a treatment called CG0070, a virus-based therapy given directly into the bladder, after standard surgery for intermediate-risk non-muscle invasive bladder cancer. About 20 participants will receive the treatment to see if it is safe and helps prevent …
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could an immune booster before kidney surgery keep cancer away?
Disease control OngoingThis phase 3 trial tests whether adding the immune-boosting drug nivolumab before and after kidney cancer surgery can prevent the cancer from coming back. About 819 patients with localized kidney cancer are randomly assigned to receive either surgery alone or surgery plus nivolum…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy boosts bladder cancer treatment in major trial
Disease control OngoingThis Phase III trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer that hasn't spread. About 475 participants receive either chemoradiotherapy alone or with atezolizumab. The main goal is to…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could removing a catheter sooner after kidney transplant cut infection risk?
Disease control OngoingThis trial compares removing a urinary catheter on day 3 versus day 6 after a living donor kidney transplant. The goal is to see if earlier removal reduces urinary tract infections within 30 days without causing more complications like urine leaks. The study involves 172 adult ki…
Phase: NA • Sponsor: Fahim Kanani • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo aims to extend life in tough bladder cancer cases
Disease control OngoingThis study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 participants will receive either the new combination …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy combo shows promise for rare childhood tumors
Disease control OngoingThis phase 2 trial is testing two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with rare INI1-negative cancers that have come back or not responded to treatment. The study aims to see if the combination can shrink tumors or slow disease progression.…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for kidney disease: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety of a drug called iptacopan for adults with a kidney disease called primary IgA nephropathy. Participants have already completed earlier studies and will continue taking the drug to monitor side effects and see if it helps slow kidney damag…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes drug shield kidneys from lupus damage?
Disease control OngoingThis phase 2 trial tests whether dapagliflozin, a drug already used for diabetes and chronic kidney disease, can slow kidney damage in people with lupus nephritis. Lupus nephritis is a serious complication of lupus that causes kidney inflammation and can lead to chronic kidney di…
Phase: PHASE1, PHASE2 • Sponsor: Hospital Civil Juan I. Menchaca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Bladder cancer breakthrough? virus therapy aims to stop recurrence
Disease control OngoingThis phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for myeloma patients with kidney failure: targeted drug tested in dialysis patients
Disease control OngoingThis study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that t…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes drug shield heart transplant patients from kidney failure?
Disease control OngoingThis trial tests whether dapagliflozin (Farxiga), a drug originally developed for diabetes, can protect kidney function in people who have received a heart transplant. Kidney failure is a common and serious complication after heart transplant. The study involves 430 participants …
Phase: PHASE3 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Immunotherapy combo aims to boost bladder cancer surgery outcomes
Disease control OngoingThis phase 3 trial tests whether adding two immunotherapy drugs—pembrolizumab and enfortumab vedotin—before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. The study includes patients who cannot take o…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Robot takes aim at bladder tumors with precision
Disease control ENROLLING_BY_INVITATIONThis study tests a robotic-assisted surgery tool to remove bladder lesions. About 30 adults with small bladder tumors will undergo the procedure. The goal is to see if the robot helps remove the tumor in one piece with healthy tissue around it, which may improve diagnosis and red…
Phase: NA • Sponsor: Virtuoso Surgical, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Cancer drug safety tracked over years in ongoing study
Disease control OngoingThis study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental cocktail aims to silence Life-Threatening food allergies
Disease control OngoingThis early-stage study tests two drugs together—linvoseltamab and dupilumab—in just 6 adults with severe food allergies. The goal is to see if the combination is safe and can lower IgE antibodies that trigger allergic reactions. Participants must have a history of anaphylaxis to …
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Lab-Made blood vessel could free dialysis patients from catheters
Disease control OngoingThis Phase 3 trial tests a lab-grown blood vessel (ATEV) against the standard surgically created fistula in 121 women with end-stage kidney disease who need dialysis. The goal is to see if the ATEV allows more days without a catheter and reduces infections over 12 months. If succ…
Phase: PHASE3 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a Two-Drug punch protect kidneys in High-Risk patients?
Disease control OngoingThis phase 3 study tests whether adding baxdrostat to the standard drug dapagliflozin can better slow chronic kidney disease (CKD) progression in adults with CKD and high blood pressure. About 2,500 participants will receive either the combination or dapagliflozin alone for 24 mo…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
PNH patients get extended access to iptacopan in safety follow-up
Disease control OngoingThis study looks at the long-term safety and tolerability of iptacopan in adults with paroxysmal nocturnal hemoglobinuria (PNH) who have already completed earlier phase 2 or 3 studies with the drug. About 208 participants will continue taking iptacopan and be monitored for side e…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New bladder cancer drug could help patients avoid bladder removal
Disease control OngoingThis phase 3 trial is testing a drug called ONCOFID-P-B for people with a type of bladder cancer that hasn't responded to standard BCG therapy. The drug is given directly into the bladder weekly for 12 weeks, then monthly for a year if it works. The goal is to see if it can contr…
Phase: PHASE3 • Sponsor: Fidia Farmaceutici s.p.a. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo tested for tough cancers
Disease control OngoingThis early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a pill keep kidney cancer away after surgery?
Disease control OngoingThis phase 3 trial tests whether the drug pazopanib can delay or prevent kidney cancer from coming back in patients who have had all visible tumors removed by surgery. 129 adults with clear cell kidney cancer that had spread are randomly assigned to take either pazopanib or a pla…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
5-year follow-up checks if imlifidase helps kidney transplants last longer
Disease control OngoingThis study follows 150 people who received imlifidase before a kidney transplant to see how long their new kidney works. Researchers will check for graft failure (return to dialysis, re-transplant, or kidney removal) over 5 years. A separate group of similar patients not receivin…
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Promising combo aims to ease bone pain in advanced kidney cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a common asthma drug shield newborns from kidney damage?
Disease control OngoingThis early study tests whether the drug theophylline can prevent kidney injury in newborns who experienced oxygen deprivation at birth (HIE) and are receiving cooling therapy. Thirty infants will receive one or two doses of theophylline within 18 hours of birth. The main goal is …
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to prevent rare melanoma recurrence
Disease control OngoingThis phase II trial tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 patients with resected mucosal melanoma will receive either nivolumab alone or nivolumab plus cabozantinib. The study aim…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for transplant patients: drug targets kidney protein leak
Disease control OngoingThis study tests a drug called sparsentan for people who have protein in their urine after a kidney transplant due to IgA nephropathy or FSGS. About 20 adults will take the drug once daily for 36 weeks to see if it safely reduces protein levels and protects kidney function. The g…
Phase: PHASE4 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug fabhalta tracked in kidney disease patients
Disease control OngoingThis study will follow 50 people with C3 glomerulopathy, a rare kidney disease, who are taking the drug Fabhalta. Researchers want to see how safe the drug is and how well it works in everyday clinical settings. They will track infections, side effects, and kidney function over t…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill aims to tame rare blood vessel disease
Disease control OngoingThis phase 2 trial tests whether adding the oral drug iptacopan to standard therapy (rituximab) helps people with active ANCA vasculitis achieve and maintain remission. About 84 adults with newly diagnosed or relapsed disease will receive either iptacopan or a placebo, plus stand…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Sound waves zap kidney tumors in new Non-Invasive trial
Disease control OngoingThis study tests a device that uses focused sound waves (histotripsy) to break apart kidney tumors without making any cuts. About 67 adults with a single small kidney mass (3 cm or less) that hasn't spread will be treated. The goal is to see if the tumors are completely gone afte…
Phase: NA • Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new treatment called IVS-3001, which uses a patient's own immune cells (T cells) engineered to target a protein called HLA-G found on some solid tumors. The study involves 31 adults with advanced solid tumors that have not responded to standard trea…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo aims to slow kidney disease
Disease control OngoingThis study tests whether a new drug called vicadrostat, combined with the existing drug empagliflozin, can help people with chronic kidney disease (CKD) that is getting worse. About 492 adults with CKD will be randomly assigned to start both drugs together or one after the other …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with tough cancers: entrectinib trial underway
Disease control OngoingThis study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
PNH drug iptacopan under safety microscope: infection risk tracked
Disease control OngoingThis study monitors about 200 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking iptacopan (Fabhalta). Researchers will use registry data to count infections caused by certain bacteria. The goal is to better understand the real-world safety of this medic…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to tame rare inflammatory disease
Disease control OngoingThis phase 3 trial tests whether a new drug, depemokimab, works as well as the current treatment mepolizumab for adults with a rare disease called EGPA, which causes inflammation of blood vessels. The study involves 163 participants and aims to see if depemokimab can help patient…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…
Phase: PHASE1 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New dialysis technique tested for better fluid control in kidney patients
Disease control ENROLLING_BY_INVITATIONThis study compares two types of dialysis in 64 adults with end-stage kidney disease. One group gets standard hemodialysis, the other gets hemodiafiltration, which uses both diffusion and convection to remove waste. The main goal is to see if hemodiafiltration leads to less weigh…
Phase: NA • Sponsor: Services Institute of Medical Sciences, Pakistan • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immune cell therapy takes on lupus in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new treatment called NKX019 for people with lupus, an autoimmune disease. NKX019 uses specially engineered immune cells to target and calm overactive B cells. The main goal is to check safety in about 6 participants, while also looking for signs tha…
Phase: PHASE1 • Sponsor: Hospital for Special Surgery, New York • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for FSGS: experimental drug APL2 enters Late-Stage trial
Disease control TerminatedThis study tests an experimental drug called APL2 for people with a kidney disease called FSGS. The goal is to see if APL2 can reduce protein in the urine, a sign of kidney damage. The trial has two parts: first, adults will receive APL2 openly; then, both adults and adolescents …
Phase: PHASE2, PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control OngoingThis phase 3 trial tests ravulizumab, a drug that blocks part of the immune system, against a placebo in 579 adults with IgA nephropathy—a kidney disease that can lead to kidney failure. The goal is to see if ravulizumab reduces protein in the urine and preserves kidney function …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for kids with kidney disease: drug targets dangerous phosphorus levels
Disease control TerminatedThis study tests the safety of a drug called ferric citrate in children aged 6 to 17 with chronic kidney disease who have high phosphorus levels. The drug is taken by mouth to help control phosphorus, which can cause bone and heart problems if too high. The study involves 45 chil…
Phase: PHASE3 • Sponsor: Keryx Biopharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo shows promise in advanced bladder cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 420 adults who have not had prior treatment for their advanced cancer will receive either tislelizumab plus chemo or a placebo…
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Atacicept's Long-Term promise for kidney disease
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effects of atacicept in people with IgA nephropathy, a kidney disease. Participants have already completed a previous trial with atacicept. Researchers will monitor side effects and measure kidney function over time to see if the drug …
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Cancer patients who respond to avelumab can keep taking it in this Follow-Up study
Disease control OngoingThis study offers continued access to the cancer drug avelumab (and sometimes other drugs) for people with advanced cancers like lung, ovarian, or bladder cancer who are already seeing benefits from a previous Pfizer-sponsored trial. About 77 participants will be followed for saf…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for rare blood disorder: Long-Term study of XH-S003 underway
Disease control ENROLLING_BY_INVITATIONThis study is testing the long-term safety and effectiveness of an experimental drug called XH-S003 in people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that can cause fatigue, blood clots, and other serious problems. About 26 people who have already ta…
Phase: NA • Sponsor: S-INFINITY Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a ZAP of radiation before standard care beat back metastatic kidney cancer?
Disease control OngoingThis Phase III trial tests whether giving a highly targeted form of radiation (SAbR) before standard therapy (immunotherapy or targeted pills) helps people with kidney cancer that has spread to 2-5 spots in the body live longer. About 472 participants are randomly assigned to rec…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets tumors in patients with organ failure
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail could rival standard bladder cancer therapy in major trial
Disease control OngoingThis study tests whether a combination of two chemotherapy drugs (gemcitabine and docetaxel, or GEMDOCE) works as well as the standard BCG treatment for people with a high-grade, non-muscle invasive bladder cancer that hasn't been treated before. About 870 adults will be randomly…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New transplant method aims to reduce complications in bone marrow failure patients
Disease control OngoingThis study tests a stem cell transplant method for people with acquired or inherited bone marrow failure. Donor stem cells are specially processed to remove certain immune cells, which may lower the risk of graft rejection and graft-versus-host disease. The goal is to see if this…
Phase: NA • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to wake up transplanted kidneys faster
Disease control TerminatedThis study tests a drug called pegcetacoplan in 320 adults who are getting a kidney transplant from a deceased donor and are at high risk for delayed graft function (when the kidney takes a while to start working). The goal is to see if the drug helps the kidney work sooner and r…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study tests aggressive BP management to protect heart and kidneys in cancer patients
Disease control OngoingThis phase II trial tests whether intensive blood pressure management (targeting systolic BP below 120 mmHg) is better than standard care (below 140 mmHg) for patients with advanced kidney or thyroid cancer starting anti-angiogenic TKI therapy. The study enrolls 61 participants a…
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
World's first robotic bladder transplant attempted in tiny trial
Disease control TerminatedThis early-phase trial tests whether a robotic bladder transplant from a deceased donor is feasible and safe for people with severe bladder problems. Only 5 participants will be enrolled. The main goal is to see if the transplanted bladder gets good blood flow. If it works, it mi…
Phase: NA • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation boosts immunotherapy in kidney cancer trial
Disease control OngoingThis phase 2 trial is testing whether adding precise, high-dose radiation (SBRT) to standard immunotherapy (ipilimumab and nivolumab) can help people with metastatic kidney cancer live longer without their disease getting worse. About 66 participants with intermediate or poor-ris…
Phase: PHASE2 • Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug larotrectinib tested in small trial
Disease control OngoingThis phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy drug durvalumab tested to stop bladder cancer return
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug durvalumab after surgery, chemotherapy, and radiation can help prevent bladder cancer from coming back in people with muscle-invasive bladder cancer. About 82 participants will receive either durvalumab or a placebo …
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill combo aims to keep PNH patients stable for years
Disease control OngoingThis study follows about 80 people with paroxysmal nocturnal hemoglobinuria (PNH) who have already taken danicopan in a previous trial. They will continue taking danicopan as an add-on to their standard C5 inhibitor therapy. The goal is to see if the combination remains safe and …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug candidate BG-68501 enters first human trials
Disease control OngoingThis early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets Hard-to-Treat cancers with rare gene flaw
Disease control OngoingThis study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug shows promise
Disease control TerminatedThis study tests a drug called DS-8201a (trastuzumab deruxtecan) in children, teens, and young adults whose osteosarcoma, Wilms tumor, or desmoplastic small round cell tumor has come back or not responded to treatment. The drug works like a smart bomb, attaching to cancer cells a…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for toddlers with bladder nerve damage: mirabegron trial launches
Disease control OngoingThis study tests a liquid medicine called mirabegron in children aged 6 months to 3 years who have bladder problems due to nerve damage (neurogenic detrusor overactivity). The goal is to see if the medicine helps the bladder hold more urine safely, reducing leaks and pressure. Ch…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a new drug shield hearts and kidneys in overweight people?
Disease control OngoingThis phase 3 trial is testing whether the drug retatrutide can lower the chance of serious heart problems (like heart attacks and strokes) and slow kidney disease in 10,000 overweight adults who already have heart or kidney disease. Participants receive either retatrutide or a pl…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on lupus nephritis
Disease control ENROLLING_BY_INVITATIONThis study tests a new treatment called CHT105 for people with lupus nephritis that hasn't responded to standard therapies. CHT105 uses specially engineered immune cells from healthy donors to target and destroy the faulty immune cells causing kidney damage. Fourteen adults will …
Phase: NA • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
CAR-T therapy aimed at tough kidney disease in kids — but trial never started
Disease control TerminatedThis was a planned early-stage trial to test whether anti-CD19 CAR-T cells could safely help children with multi-drug resistant nephrotic syndrome, a serious kidney condition. The study was withdrawn before any patients were enrolled, so no data on safety or effectiveness were co…
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising CAR-T trial for kids with rare vasculitis pulled before start
Disease control TerminatedThis trial aimed to test whether anti-CD19 CAR-T cells could safely and effectively treat children with refractory ANCA-associated vasculitis, a rare autoimmune disease. The study was withdrawn before enrolling any participants, so no results are available. It was designed for ch…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Combining two drugs may tackle bladder cancer that resists standard therapy
Disease control OngoingThis trial investigates whether combining two drugs—BCG and gemcitabine—can safely and effectively treat a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that has come back after previous BCG treatment. Participants receive BCG directly into the bladder …
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to outdo chemo for advanced bladder cancer
Disease control OngoingThis phase 3 study tests whether a combination of disitamab vedotin and pembrolizumab works better than standard chemotherapy for people with advanced bladder cancer that has spread. The cancer must have a protein called HER2. About 412 participants will be randomly assigned to e…
Phase: PHASE3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study checks kidney impact on prostate cancer drug safety
Disease control OngoingThis study looks at how well the body handles a radioactive drug (lutetium vipivotide tetraxetan) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if different levels of kidney function change how the drug spr…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug fabhalta under safety watch for rare blood disorder
Disease control OngoingThis study tracks 132 people with PNH who are taking Fabhalta to see how safe it is and what side effects occur. Researchers will monitor infections and check for serious red blood cell breakdown if the drug is stopped. The goal is to better understand the drug's risks in everyda…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New implant aims to stop Post-Prostate surgery leaks
Disease control OngoingThis study follows 100 men who have had prostate surgery and still struggle with stress urinary incontinence (leaking urine when coughing or moving). They receive an adjustable implant called REMEEX to help control leakage. Researchers will track how well it works, side effects, …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis early-stage trial is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. KITE-363 is a type of cell therapy where a patient's own immune cells are modified in a lab to t…
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
No more charging: new implant aims to ease bladder and bowel leaks
Disease control OngoingThis study is testing a new, recharge-free nerve stimulator (Axonics SNM system) in 144 adults with overactive bladder or fecal incontinence. The device is implanted to stimulate sacral nerves and improve control. Researchers will measure quality of life and symptom changes over …
Phase: NA • Sponsor: Axonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo shows promise for tough bladder cancer
Disease control OngoingThis study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. About 30 adults with locally advanced or metastatic uro…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…
Phase: PHASE1 • Sponsor: Rondo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a Pre-Surgery drug tame metastatic kidney cancer?
Disease control OngoingThis phase 2 trial is studying whether giving the drug sunitinib before surgery to remove a kidney can help control metastatic renal cell carcinoma. About 50 patients with kidney cancer that has spread will take sunitinib for 28 days, then have the affected kidney removed. Resear…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Real-World ravulizumab data: hope for PNH patients in poland
Disease control OngoingThis study follows 64 Polish adults with paroxysmal nocturnal hemoglobinuria (PNH) who are taking ravulizumab as part of their routine care. Researchers will track blood markers like LDH and how many patients need blood transfusions over time. The goal is to see if the drug works…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Surgery vs. diet: which tames diabetes better?
Disease control OngoingThis study compares two types of weight-loss surgery (gastric bypass and gastric banding) with an intensive diet and exercise program for controlling type 2 diabetes in moderately obese adults aged 25 to 55. The goal is to see which approach works best for improving diabetes and …
Phase: NA • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Two-Drug maintenance strategy aims to stall advanced bladder cancer
Disease control OngoingThis phase III trial tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from growing after initial chemotherapy. About 654 patients will receive either the combination or avelumab alone as maintenance therapy. The goal is to s…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Which vaginal estrogen works best for recurrent UTIs? new study aims to find out
Disease control OngoingThis study looks at how well women with low estrogen (like after menopause) stick to using vaginal estrogen treatments to prevent repeat urinary tract infections. About 111 women will be randomly assigned to use a cream, tablet, or ring. Researchers will track adherence over 6 mo…
Phase: PHASE4 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug aims to fix calcium levels in rare genetic disease
Disease control OngoingThis study tests a new drug called encaleret against usual treatments for people with a rare genetic condition called autosomal dominant hypocalcemia type 1 (ADH1), which causes low blood calcium and high urine calcium. About 67 participants will receive either encaleret or stand…
Phase: PHASE3 • Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Targeted drug shows promise for Hard-to-Treat bladder cancers
Disease control OngoingThis study tests a drug called olaparib in 60 people with advanced bladder or related cancers that have specific DNA repair defects. Olaparib blocks a protein that cancer cells need to fix their DNA, which may stop the cancer from growing. The goal is to see if the drug can shrin…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo aims to fight tough bladder cancer
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New study tests everolimus for kidney tumors in TSC patients
Disease control OngoingThis study looks at how safe and effective the drug everolimus is for Taiwanese adults with tuberous sclerosis complex (TSC) who have kidney tumors called angiomyolipomas. Four participants will take the drug and be monitored for side effects and tumor shrinkage. The goal is to c…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Promising drug cocktail eyed for Tough-to-Treat urinary cancer
Disease control ENROLLING_BY_INVITATIONThis study looks at how well a combination of two drugs (enfortumab vedotin and pembrolizumab) works as a first treatment for people with advanced upper tract urothelial carcinoma, a rare cancer of the urinary tract. Researchers will track 50 patients in France to see how many re…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New immunotherapy shows promise against multiple advanced cancers
Disease control OngoingThis study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can a sedative shield kidneys during aortic surgery?
Disease control OngoingThis early-stage trial tests whether the drug dexmedetomidine can reduce acute kidney injury in 78 adults undergoing ascending aortic surgery with a heart-lung machine. Half receive the drug, half get a placebo. The goal is to see if the drug's anti-inflammatory effects help prev…
Phase: PHASE1 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New targeted pill shows promise for tough bladder cancers
Disease control OngoingThis study tests a targeted pill (erdafitinib) against standard chemotherapy or immunotherapy in people with advanced bladder cancer that has specific FGFR gene changes. About 629 participants whose cancer worsened after prior treatments will be randomly assigned to receive erdaf…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug duo aims to boost immune attack on tough cancers
Disease control OngoingThis early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Bladder cancer patients may skip surgery with new drug combo
Disease control OngoingThis phase 3 trial tests a new approach for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. Participants receive either a combination of TAR-200 (a drug placed directly into the bladder) plus cetrelimab (an immunotherapy), or sta…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New bladder cancer device could delay return of tumors without removing bladder
Disease control OngoingThis study tests a new treatment called TAR-200 for people with a high-risk type of bladder cancer that came back after standard therapy (BCG). Participants either receive TAR-200 or standard chemotherapy placed directly into the bladder. The goal is to see if TAR-200 can keep th…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo aims to wipe out kidney cancer before surgery
Disease control OngoingThis study tests whether giving two drugs—nivolumab (immunotherapy) and cabozantinib (targeted therapy)—before removing the kidney can make all visible cancer disappear in people with advanced kidney cancer that has spread. About 38 adults with metastatic renal cell carcinoma wil…
Phase: PHASE2 • Sponsor: Mark Stein • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Sling surgery for bladder leakage tracked for a decade
Disease control OngoingThis study follows about 200 women who had surgery with the GYNECARE TVT EXACT sling to treat stress urinary incontinence (leaking urine when coughing or sneezing). Researchers check if the sling still works 5 to 10 years later by using a cough test and patient questionnaires. Th…
Sponsor: Ethicon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for bladder cancer patients avoiding bladder removal
Disease control OngoingThis study tests two experimental treatments—TAR-200 (a drug placed inside the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in people with high-risk bladder cancer that came back after BCG therapy. Participants are those who cannot or choose not to have…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New bladder cancer combo aims to beat standard treatment
Disease control OngoingThis phase 3 trial tests two new approaches for high-risk bladder cancer that hasn't spread into the muscle. One group gets a drug called TAR-200 placed directly into the bladder plus an immunotherapy drug (cetrelimab). Another group gets TAR-200 alone. These are compared to the …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for bladder cancer patients who Can't take standard chemo
Disease control OngoingThis phase 3 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a targeted therapy (enfortumab vedotin) works better than current standard care for people with muscle-invasive bladder cancer who cannot take or refuse cisplatin chemotherapy. A…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Zapping just a few spots: new hope for patients with worsening metastatic cancer?
Disease control OngoingThis study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug shows promise for Hard-to-Treat bladder cancer
Disease control OngoingThis phase 2 trial tests a drug called erdafitinib in 239 people with advanced bladder cancer that has certain FGFR gene changes. The drug aims to shrink tumors by blocking signals that help cancer grow. Researchers are checking how well it works and what side effects occur.
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New bladder cancer drug delivery system tested in small japanese study
Disease control OngoingThis early-stage study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is…
Phase: PHASE1 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a simple shot replace IV drips for some cancer patients?
Disease control OngoingThis early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug aims to slow kidney failure in common kidney disease
Disease control OngoingThis phase 3 trial tests whether the drug atrasentan can slow kidney function loss in people with IgA nephropathy, a disease that can lead to kidney failure. About 404 participants receive either atrasentan or a placebo, along with standard care. The main goal is to see if atrase…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Supplement shows promise for kidney Patients' heart health
Disease control OngoingThis study tests whether a natural supplement called nicotinamide riboside can improve artery stiffness and lower blood pressure in people with moderate to severe chronic kidney disease. About 118 adults aged 35-80 will take either the supplement or a placebo for 3 months. The go…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take aim at multiple cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibiotic vabomere tested in kids with tough UTIs
Disease control OngoingThis study tests the safety of an antibiotic called Vabomere in children aged 3 months to 12 years who have complicated urinary tract infections, including kidney infections. The children receive the medicine through an IV while in the hospital. Researchers monitor for side effec…
Phase: PHASE2 • Sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New shot could shrink enlarged livers and ease pain
Disease control OngoingThis study tests a drug called CAM2029 (octreotide) given as a weekly or every-other-week shot to people with symptomatic polycystic liver disease. The goal is to see if it can shrink the liver and reduce symptoms like belly pain, bloating, and nausea. About 71 adults with an enl…
Phase: PHASE2, PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a cancer therapy tame severe lupus? early trial launches
Disease control OngoingThis early-phase trial is testing a new treatment called YTB323, a type of CAR T-cell therapy, in 21 adults with severe lupus that hasn't improved with standard treatments. The goal is to see if a single infusion is safe and can control the disease. Researchers will also measure …
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug zanubrutinib takes on kidney disease in major trial
Disease control OngoingThis study tests whether the drug zanubrutinib can help people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 178 participants will receive either zanubrutinib or the standard drug tacrolimus. The goal is to see if zanubrutinib reduces pr…
Phase: PHASE2, PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for advanced cancers: JANX008 enters human testing
Disease control OngoingThis early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a simple supplement protect hearts in kidney failure?
Disease control OngoingThis study tests whether a special form of calcium and magnesium (effervescent calcium-magnesium citrate) can slow down harmful calcium buildup in the heart and blood vessels of people with end-stage kidney disease on dialysis. About 269 adults will take either this supplement or…
Phase: PHASE2, PHASE3 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to shrink kidney tumors before surgery
Disease control OngoingThis early-phase study tests whether giving immunotherapy drugs (nivolumab alone or with bevacizumab or ipilimumab) before surgery is safe for people with advanced kidney cancer that has spread. About 104 participants will receive one of these treatments before their tumor is rem…
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New device aims to ease enlarged prostate for years
Disease control OngoingThis study follows 60 men with an enlarged prostate who already used the Butterfly device for a year. Researchers will track safety and symptom relief for up to 5 years. The goal is to see if the device remains effective and safe over the long term.
Phase: NA • Sponsor: Butterfly Medical Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Dialysis dilemma: which access surgery is safer for seniors?
Disease control OngoingThis study compares two types of surgery to create dialysis access in older adults (60+) with end-stage kidney disease. One method connects a vein directly to an artery (fistula), the other uses a synthetic tube (graft). The goal is to see which leads to fewer infections and more…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody drug could open door to kidney transplants for Hard-to-Match patients
Disease control OngoingThis study tests a drug called vonsetamig in 43 people with chronic kidney disease who are on dialysis and have very high levels of anti-HLA antibodies, making it nearly impossible to find a matching kidney donor. The drug aims to safely lower these antibodies so that a kidney tr…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to plug kidney leaks in multiple diseases
Disease control OngoingThis phase 2 study tests the drug atrasentan in 103 adults with various kidney diseases that cause protein leakage, including IgA nephropathy and FSGS. Participants take a daily tablet to see if it reduces protein in urine, a sign of kidney damage. The goal is to find a new way t…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to boost immune attack on kidney cancer
Disease control OngoingThis study tests whether adding an experimental drug (PF-04518600) that boosts the immune system to the standard drug axitinib can help control advanced kidney cancer better than axitinib alone. About 62 adults whose cancer has spread and who have already tried an immune checkpoi…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can simple tools help cancer survivors live healthier?
Disease control OngoingThis study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a Pre-Transplant HPV shot shield patients from cancer?
Disease control OngoingThis phase 2 trial tests whether giving the HPV vaccine (Gardasil 9) to adults before a kidney transplant helps their immune system fight HPV after transplant, when they must take drugs that weaken immunity. About 51 participants will receive the vaccine before surgery, and resea…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug targets Hard-to-Treat cancers in major trial
Disease control OngoingThis study tests a new drug called raludotatug deruxtecan (R-DXd) in 200 adults with advanced or spreading solid tumors, including certain ovarian, cervical, endometrial, bladder, and kidney cancers. The goal is to see if the drug can shrink tumors or stop them from growing. Part…
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo aims to unleash immune system against tough ovarian cancer
Disease control OngoingThis study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…
Phase: PHASE1, PHASE2 • Sponsor: Alexander B Olawaiye, MD • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail aims to outperform chemo for advanced bladder cancer
Disease control OngoingThis phase 3 study tests whether a combination of two drugs, enfortumab vedotin and pembrolizumab, works better than standard chemotherapy for people with advanced urothelial cancer that has spread. About 886 participants who have not had prior treatment for their advanced cancer…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New immunotherapy cocktail aims to fight advanced bladder cancer
Disease control OngoingThis large Phase 3 trial is testing whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy can help people with advanced bladder cancer that cannot be removed by surgery. Over 1,200 participants worldwide are receiving either che…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for kidney transplant patients battling BK virus
Disease control OngoingThis study looks at two drug combinations to treat BK virus infection in kidney transplant recipients. BK virus can cause the new kidney to fail. The trial compares everolimus with a lower dose of tacrolimus versus a lower dose of tacrolimus plus leflunomide in 50 adults whose vi…
Phase: NA • Sponsor: King Chulalongkorn Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for kids with tough kidney disease: obinutuzumab may replace steroids
Disease control OngoingThis study tests a new drug called obinutuzumab in 100 children aged 1-18 with refractory nephrotic syndrome, a kidney condition causing swelling and protein loss. The drug targets immune cells to reduce disease flares and dependence on steroids and other medications. Researchers…
Sponsor: Children's Hospital of Chongqing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for rare disease: can NS-229 help patients reduce steroids?
Disease control OngoingThis study tests a new medicine, NS-229, in 45 adults with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA), which causes inflammation in blood vessels. The goal is to see if NS-229 can help patients achieve remission while lowering their daily steroid d…
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug targets rare gene fusions in multiple cancers
Disease control OngoingThis phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a testosterone shot before surgery speed recovery?
Disease control OngoingThis early-phase trial is testing whether giving testosterone replacement therapy to men with low testosterone before and after major urologic surgery is safe and might improve recovery. Researchers will track quality of life, frailty, complications, hospital stay length, and rea…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Bladder cancer duo: BCG plus immunotherapy drug shows promise in early trial
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard BCG treatment can safely control high-risk non-muscle-invasive bladder cancer. About 100 adults who have never received BCG before will get both treatments for up to a year. The main goal i…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
MRNA cancer shots: new hope or hype?
Disease control OngoingThis early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for advanced bladder cancer: experimental drug combo enters late-stage trial
Disease control OngoingThis study tests an experimental drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced urothelial cancer that has spread. The goal is to see if it works better than standard chemotherapy. About 375 participants will be enrolled, some who have not…
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a High-Fat diet help cancer immunotherapy work better?
Disease control TerminatedThis early-phase trial is testing whether a ketogenic diet (low carbs, high fat) can safely help immunotherapy drugs work better in people with advanced melanoma or kidney cancer. About 60 participants will follow the diet while receiving standard immunotherapy. The main goals ar…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo shows promise against advanced kidney cancer
Disease control OngoingThis study tests a combination of two drugs, nivolumab and axitinib, in people with advanced kidney cancer. The goal is to find the safest dose and see how well the drugs shrink tumors. About 98 participants will take part, including those who have had prior treatment and those w…
Phase: PHASE1, PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for rare kidney cancer: drug combo shows promise in late-stage trial
Disease control OngoingThis phase 3 study tests whether combining two drugs (savolitinib and durvalumab) works better than the standard drug sunitinib for people with a rare, advanced kidney cancer called papillary renal cell carcinoma that has a specific genetic change (MET-driven). About 148 adults w…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Immunotherapy boosts bladder cancer treatment, early trial shows promise
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. The goal is to see if the combination helps shrink tumors and allows patie…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New cancer drug shows promise in early trial
Disease control OngoingThis early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New shot could tame lupus kidney flares
Disease control OngoingThis phase 3 trial tests whether adding ianalumab (a biologic injection) to standard therapy helps control active lupus nephritis, a serious kidney complication of lupus. About 452 adults with active lupus nephritis are receiving either ianalumab every 4 or 12 weeks or a placebo,…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a Plant-Based diet protect transplanted kidneys?
Disease control OngoingThis study looks at whether switching to a plant-based diet can improve heart health and reduce inflammation in people who have had a kidney transplant. Twenty-five participants who are at least three months post-transplant will follow a plant-based diet for 16 weeks after a two-…
Phase: NA • Sponsor: George Washington University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug aims to shield kidneys from dye damage during heart surgery
Disease control OngoingThis study tests whether the drug APX-115 can prevent kidney injury caused by contrast dye used in heart procedures. About 230 adults with kidney disease will receive either the drug or a placebo before and after their procedure. The goal is to see if the drug reduces kidney dama…
Phase: PHASE2 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug duo takes on tough cancers
Disease control OngoingThis early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people whose prostate, bladder, or kidney cancer has spread. The main goals are to find the safest dose and see what side effects occur. About 65 participants will receive both drugs t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a diabetes drug protect the heart and kidneys in severe CKD?
Disease control ENROLLING_BY_INVITATIONThis Phase 3 trial tests whether dapagliflozin (Forxiga), a drug originally for diabetes, can reduce the risk of death, kidney failure, and heart failure hospitalization in 1750 people with severe chronic kidney disease. Unlike earlier studies, this trial includes patients on dia…
Phase: PHASE3 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo offers hope for kidney cancer patients who stopped responding to immunotherapy
Disease control OngoingThis study tests a combination of two drugs, cadonilimab and lenvatinib, in 28 adults with advanced clear cell kidney cancer that worsened after initial immunotherapy. The goal is to see if the combo can shrink tumors or slow disease progression. Participants receive treatment un…
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a 3-Day drug cocktail rejuvenate kidney patients?
Disease control ENROLLING_BY_INVITATIONThis study tests whether a short course of two drugs, dasatinib and quercetin, can clear senescent (aging) cells in people with chronic kidney disease. The goal is to see if this reduces frailty and improves stem cell function. Thirty participants aged 40-80 with moderate-to-seve…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New balloon could ease urinary blockages without surgery
Disease control OngoingThis study tests a special balloon coated with the drug paclitaxel to treat urethral stricture, a narrowing of the urine tube in men. The balloon is inflated to open the stricture and deliver the drug to prevent it from closing again. The trial involves 127 men who have had at le…
Phase: NA • Sponsor: Urotronic Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Bladder cancer combo trial pulled before it began
Disease control TerminatedThis study aimed to see if adding ANKTIVA to standard BCG treatment works better than BCG alone for people with a high-grade type of bladder cancer that hasn't spread into the muscle. It was designed for adults with papillary tumors who had not received BCG before or had limited …
Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for kidney cancer: drug cocktails aim to shrink tumors
Disease control OngoingThis clinical trial is testing several new combinations of drugs for people with advanced kidney cancer that has spread. The study includes about 400 participants who have not had any prior treatment for their advanced disease. The goal is to see if these combinations are safe an…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Brazil nuts tested as Anti-Inflammatory aid for kidney disease
Disease control OngoingThis study is testing whether eating Brazil nuts can reduce inflammation and oxidative stress in people with chronic kidney disease. Fifty patients will take Brazil nut supplements for six months while researchers measure changes in blood and gut bacteria. It is a small, early-st…
Phase: NA • Sponsor: Universidade Federal Fluminense • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New kidney stone surgery could be just as effective, less invasive
Disease control OngoingThis study compares two procedures for removing 1-2 cm kidney stones from the lower part of the kidney. One method uses a thin tube with a camera through the urinary tract, while the other makes a small incision in the back. The goal is to see if the less invasive approach works …
Phase: NA • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for rare blood disorder: crovalimab trial underway
Disease control OngoingThis study tests a new medicine, crovalimab, for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. It involves healthy volunteers and people with PNH to check safety and how well the drug works. The goal is to control the disease, not …
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control OngoingThis phase 3 trial tests whether the drug povetacicept can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a kidney disease. About 605 participants will receive either the drug or a placebo by injection. The study is active but not recruit…
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo aims to fight tough bladder cancer
Disease control OngoingThis phase II trial is testing whether adding the immunotherapy drug pembrolizumab to the chemotherapy drug gemcitabine can help patients with a type of bladder cancer that does not respond to the usual BCG treatment. The study involves 161 participants and looks at how many pati…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo aims to outsmart Hard-to-Treat kidney cancer
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib helps people with advanced papillary kidney cancer live longer without their disease getting worse. About 200 participants will receive either cabozantinib alone or cabo…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail targets Hard-to-Treat bladder cancer
Disease control OngoingThis early-phase trial is testing a combination of two drugs—erdafitinib and enfortumab vedotin—in 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. Erdafitinib blocks a faulty protein that helps cancer grow, while enfortumab vedotin de…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to starve and attack tumors in advanced cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug targets genetic weakness in bladder cancer
Disease control OngoingThis phase 2 trial tests a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific genetic change (TSC1 or TSC2 mutation). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors and h…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Kidney cancer combo aims to stop recurrence after surgery
Disease control OngoingThis phase 3 trial tests whether adding belzutifan to standard pembrolizumab after kidney cancer surgery can delay or prevent the cancer from coming back. About 1800 participants with clear cell renal cell carcinoma are randomly assigned to receive either belzutifan plus pembroli…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New study aims to slow kidney disease with coaching and subsidies
Disease control OngoingThis study looks at whether a combination of nurse health coaching, doctor training, and subsidies for a kidney-protecting drug can help slow the worsening of chronic kidney disease. About 724 adults with moderate-to-severe kidney disease in Singapore will be randomly assigned to…
Phase: NA • Sponsor: Duke-NUS Graduate Medical School • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for advanced kidney cancer: belzutifan takes on everolimus in major trial
Disease control OngoingThis phase 3 trial compares the experimental drug belzutifan to the standard drug everolimus in 755 people with advanced kidney cancer that has worsened after prior treatments. The goal is to see if belzutifan can better delay cancer growth and improve survival. Participants take…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug duo targets rare kidney cancer in early trial
Disease control OngoingThis study tests a combination of two drugs (fruquintinib and serplulimab) as the first treatment for people with a rare type of kidney cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors or slow the disease. About 39 adults will t…
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can cinnamon tame kidney disease inflammation?
Disease control OngoingThis study looks at whether taking cinnamon supplements for three months can lower inflammation and improve gut health in people with chronic kidney disease. Thirty patients will take either cinnamon capsules or a placebo. Researchers will measure markers of inflammation and oxid…
Phase: NA • Sponsor: Universidade Federal Fluminense • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy may shield diabetic kidneys from damage
Disease control OngoingThis study tests whether adding an SGLT2 inhibitor to standard ARB therapy better reduces protein in the urine (a sign of kidney damage) in diabetic patients without high blood pressure. Sixty adults aged 30-60 with diabetes and microalbuminuria will receive either ARBs alone or …
Phase: PHASE2, PHASE3 • Sponsor: Dr Mudassar Saeed Pansota • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy targets rare childhood and adult cancers
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults with rare cancers that have come back or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), making them hard to treat. The goal is to see if the drug com…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New pill combo aims to slow kidney decline in High-Risk patients
Disease control OngoingThis Phase 3 trial tests whether adding zibotentan to the standard drug dapagliflozin can better protect kidney function in people with chronic kidney disease and high proteinuria. About 1,800 adults are taking either the combo or dapagliflozin alone. The main goal is to see if t…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug crovalimab aims to control rare blood disorder PNH
Disease control OngoingThis phase 3 trial tests crovalimab in about 50 people with PNH who have not used similar drugs before. PNH causes red blood cells to break apart, leading to fatigue, pain, and need for transfusions. Crovalimab is given as an IV infusion and then as injections under the skin to b…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise for lupus kidney patients in major trial
Disease control OngoingThis study tests a drug called obinutuzumab for people with lupus nephritis, a kidney disease caused by lupus. About 271 participants receive either the drug or a placebo, added to their usual treatment. The goal is to see if the drug helps achieve complete kidney response, meani…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for bladder cancer patients who Can't take chemo?
Disease control OngoingThis Phase 2 trial is testing whether combining two drugs, durvalumab (an immunotherapy) and olaparib (a targeted therapy), can help people with advanced bladder cancer who are not healthy enough for standard platinum chemotherapy. About 154 participants will receive either the d…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could less steroid be just as good for kids with kidney disease?
Disease control OngoingThis study tests whether a lower dose of the steroid prednisone can treat relapses of nephrotic syndrome in children as effectively as the standard dose. Fifty children aged 1 to 18 with active relapses will be randomly assigned to either the reduced-dose or standard-dose regimen…
Phase: PHASE3 • Sponsor: The Hospital for Sick Children • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug could simplify treatment for rare EGPA disease
Disease control OngoingThis study tests whether a newer drug, benralizumab, works as well as the current standard, mepolizumab, for people with a rare disease called EGPA that inflames blood vessels. About 140 adults with active EGPA will receive either drug for a year, along with their usual steroids.…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug duo takes on tough cancers: hope for advanced bladder, kidney, and melanoma patients
Disease control OngoingThis study is testing a new combination of two immunotherapy drugs (BGB-A445 and tislelizumab) in about 113 people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the combo can shrink tumors and how safe it is. Participants must have already t…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New cocktail of drugs shows promise for tough kidney cancer
Disease control OngoingThis study tests whether combining newer immunotherapy drugs with a standard targeted therapy (axitinib) can safely control advanced kidney cancer. About 199 adults with untreated, advanced clear-cell renal cell carcinoma will receive one of three drug combinations. The main goal…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Supercharged immune cells take on advanced kidney and bladder tumors
Disease control OngoingThis early-phase study tests a new immune therapy for people with advanced kidney or bladder cancer. Researchers take a person's own natural killer cells, train them in the lab to better recognize cancer, and give them back along with a protein that boosts immune activity. The ma…
Phase: EARLY_PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for bladder cancer patients who Can't take chemo
Disease control OngoingThis study tests whether combining radiation therapy with immunotherapy drugs (durvalumab with or without tremelimumab) can help people with advanced bladder cancer who cannot or will not have chemotherapy. The trial includes 13 participants with cancer that has spread or cannot …
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Bladder cancer patients may avoid surgery with new drug
Disease control OngoingThis study tests a drug called UGN-102 for people with a low-grade type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder to destroy tumors without surgery. The main goal is to see if the cancer disappears completely after 3 months.…
Phase: PHASE3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New study aims to tame high potassium in kidney patients with standardized care
Disease control OngoingThis study tests whether a standardized care plan can help chronic kidney disease patients better control high potassium levels while optimizing their RAASi medications. About 1,000 participants will receive the care plan, which includes doctor training and patient education. The…
Phase: NA • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New triple therapy for bladder cancer shows promise in early trial
Disease control OngoingThis early-phase study tests a combination of three drugs (tremelimumab, durvalumab, and belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understand side effects. About 9 adults who ha…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Scientists reprogram immune cells to attack common cancer mutation
Disease control OngoingThis early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could a diabetes drug protect kidneys in obesity? new trial investigates
Disease control OngoingThis Phase 2 trial tests whether tirzepatide, a drug already used for diabetes and weight loss, can improve kidney health in 140 people with obesity and chronic kidney disease (with or without type 2 diabetes). Researchers will use MRI scans to measure changes in kidney fat and b…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a Pre-Surgery drug shrink kidney tumors?
Disease control OngoingThis phase 2 trial is testing whether the drug cabozantinib can shrink tumors in 22 people with advanced kidney cancer before they have surgery. The goal is to see if the drug reduces tumor size enough to improve surgical outcomes and delay cancer return. Participants take caboza…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise for slowing kidney disease in IgA nephropathy patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called sibeprenlimab for people with IgA nephropathy, a kidney disease. About 600 adults who completed earlier trials of this drug will continue receiving it for up to 2 more years. Researchers will track side effects and measure…
Phase: PHASE2, PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New PNH drug VSA012 enters early human testing
Disease control OngoingThis early-stage trial tests a new drug called VSA012 in about 50 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The study includes people who have not used complement inhibitors before or who still have low hemoglobin …
Phase: PHASE1 • Sponsor: Bisirna Therapeutics Pte. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Tiny study tests radiation boost to immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis pilot study tested whether adding low-dose radiation (brachytherapy) to standard immunotherapy could help shrink tumors in people with advanced melanoma, kidney cancer, or urothelial cancer. Only 5 participants were enrolled, and the main goal was to see how many responded t…
Phase: PHASE1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a special drink cut surgery complications in bladder cancer?
Disease control OngoingThis phase III trial tests whether an immune-enhancing nutritional supplement, taken before and after bladder cancer removal surgery, can reduce post-operative complications and infections. About 203 participants are randomly assigned to receive either the supplement or a placebo…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for kidney cancer: drug duo takes on tough tumors
Disease control OngoingThis phase 3 trial compares a combination of two drugs, belzutifan and lenvatinib, against the standard drug cabozantinib in 747 people with advanced kidney cancer that has worsened after initial treatment. The goal is to see if the combo can better slow cancer growth or improve …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a single cell infusion replace lifelong Anti-Rejection drugs?
Disease control OngoingThis early-phase study tests whether a single infusion of special immune cells (regulatory dendritic cells) from the kidney donor can help the recipient's body accept the new kidney with fewer side effects. 14 first-time kidney transplant recipients will receive the cells one wee…
Phase: PHASE1 • Sponsor: Angus W. Thomson PhD DSc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for advanced kidney cancer: Triple-Drug combo shows promise
Disease control OngoingThis study tests if adding another drug (belzutifan or quavonlimab) to a standard two-drug treatment can help people with advanced clear cell kidney cancer live longer or stop their cancer from growing. About 1,650 adults who have not had prior treatment for advanced disease will…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug aimed at Kidney-Lung crisis shows promise in trial
Disease control OngoingThis study tests an experimental drug called Auxora in 150 adults with acute kidney injury and breathing failure. Patients receive either Auxora or a placebo daily for five days. The goal is to see if Auxora helps patients survive, breathe without a machine, and avoid kidney dial…
Phase: PHASE2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a targeted drug beat standard care for shock in liver patients?
Disease control OngoingThis study tests whether a drug called Angiotensin II can raise blood pressure more effectively than standard medications in people with liver cirrhosis who have septic shock. Researchers will measure how well the heart and blood vessels work together over 24 hours. The trial inv…
Phase: EARLY_PHASE1 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could zapping kidney nerves tame tough high blood pressure?
Disease control OngoingThis study tests a device that uses radiofrequency energy to calm overactive kidney nerves, which can drive high blood pressure. About 1,900 adults with uncontrolled hypertension will receive the procedure and be followed for years. The goal is to see if this approach safely and …
Phase: NA • Sponsor: Medtronic Vascular • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could zapping kidney nerves tame tough blood pressure in polycystic kidney disease?
Disease control OngoingThis study tests a device that uses ultrasound to burn nerves around the kidney arteries, aiming to lower blood pressure in people with autosomal dominant polycystic kidney disease (ADPKD) whose blood pressure remains high despite medication. 44 participants will be randomly assi…
Phase: NA • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Blood-Clot monitor could cut transfusions in heart surgery
Disease control OngoingThis study tests whether a bedside device called Quantra can help doctors decide when to give blood transfusions during complex heart surgery. The device measures how well a patient's blood clots in real time. Researchers hope this will reduce the number of blood products (like r…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Heated chemo during surgery shows promise for rare abdominal cancer
Disease control OngoingThis phase 2 trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help people with a rare and aggressive adrenal cancer that has spread within the belly. About 30 participants will have surgery to remove visible tumors, followed by a wash of…
Phase: PHASE2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for advanced kidney cancer: experimental combo therapies under study
Disease control OngoingThis study is testing experimental combinations of drugs for people with advanced kidney cancer (clear cell type) that has gotten worse after initial treatment. The goal is to see if these combinations are safe and can shrink tumors. About 370 participants will be enrolled in thi…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New approach aims to drain hidden sodium in dialysis patients
Disease control OngoingThis pilot study tests whether adding a special type of dialysis (peritoneal dialysis) between regular hemodialysis sessions can remove extra sodium and fluid from the body. Ten adults on hemodialysis will receive this extra treatment twice a week for three weeks. Researchers wil…
Phase: PHASE2 • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Immunotherapy combo shows promise against tough bladder cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard BCG treatment helps people with high-risk non-muscle invasive bladder cancer stay cancer-free longer. About 1,400 participants will receive either BCG alone or BCG plus pembrolizumab. The goal is to …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a diabetes pill slow kidney cyst growth? new study tests safety
Disease control OngoingThis study tests whether empagliflozin, a drug used for diabetes, is safe and tolerable for people with autosomal dominant polycystic kidney disease (ADPKD). About 50 adults with moderate kidney function will receive either the drug or a placebo for 12 months. Researchers will mo…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Immunotherapy plus chemoradiation may help bladder cancer patients keep their bladder
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help people with muscle-invasive bladder cancer live longer without their cancer returning or spreading. About 520 participants who are eligible for non-surgical treatment will …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New antibody drug takes on advanced cancers in first human trial
Disease control OngoingThis early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …
Phase: PHASE1 • Sponsor: Nectin Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug duo aims to tame rare blood disorder
Disease control OngoingThis study tests a combination of two experimental drugs, pozelimab and cemdisiran, for people with PNH, a rare blood disease that destroys red blood cells. The goal is to see if this combo works better and is safer than current standard treatments (ravulizumab and eculizumab). A…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Sling or no sling? study tests two surgical fixes for leaky bladder
Disease control OngoingThis study compares two surgical procedures for stress urinary incontinence (leaking urine when coughing, sneezing, or lifting). One uses a mesh tape (transvaginal tape), the other tightens the urethral ligaments without mesh. Researchers will follow 200 women for one year to see…
Phase: NA • Sponsor: Sanliurfa Education and Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New PNH drug crovalimab faces off against eculizumab in phase 3 trial
Disease control OngoingThis phase 3 trial compares crovalimab, a new injectable drug, to eculizumab in about 190 people with paroxysmal nocturnal hemoglobinuria (PNH) who are already on complement inhibitors. The study aims to see if crovalimab is as safe and effective, with a focus on side effects and…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Old asthma drug shows promise for rare genetic disorder
Disease control OngoingThis phase 2 trial tests whether theophylline, a drug used for asthma, can help people with pseudohypoparathyroidism lose weight and improve blood sugar control. The study includes 29 obese participants aged 13 and older. Researchers will measure changes in body mass index and gl…
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Engineered immune cells take on kidney cancer in early trial
Disease control OngoingThis early-phase study tests a new gene therapy for people with advanced clear cell kidney cancer. Doctors take a patient's own white blood cells, modify them in the lab to better attack cancer, and return them to the body. The main goals are to check safety and see if tumors shr…
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New PNH drug crovalimab tested against standard care in phase 3 trial
Disease control OngoingThis study tests whether crovalimab works as well as eculizumab for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. About 210 adults who have not had prior complement inhibitor therapy will receive either drug. The main goals are to see if crovalimab…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New dialysis graft aims to reduce blockages and infections
Disease control OngoingThis study tests a new device called STARgraft-3, a tube used for dialysis in people with end-stage kidney disease. The goal is to see if it stays open longer and resists infection better than standard grafts. About 21 adults will be followed for up to a year to check how well th…
Phase: NA • Sponsor: Healionics Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug shows promise for rare blood vessel disease
Disease control OngoingThis study tests a drug called tezepelumab in 42 adults with EGPA, a rare disease that causes inflammation in blood vessels and can damage organs. The goal is to see if the drug helps patients reach remission, meaning no active disease and low steroid use. Participants receive ei…
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can a dialysis boost fix malnutrition in kidney patients?
Disease control ENROLLING_BY_INVITATIONThis study tests a special dialysis fluid containing amino acids (protein building blocks) to see if it can improve the nutritional status of adults with end-stage kidney disease who are on peritoneal dialysis. About 50 participants will replace one daily dialysis bag with this s…
Phase: PHASE4 • Sponsor: Shanghai 10th People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could shorter antibiotic courses be better for hospitalized kids?
Disease control ENROLLING_BY_INVITATIONThis study aims to find out if 5 days of antibiotics works as well as 10 days for children hospitalized with pneumonia, skin infections, or urinary tract infections. About 1,200 children will be randomly assigned to either a 5-day or 10-day course, with some receiving a placebo a…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a common asthma drug help treat a rare genetic disorder?
Disease control ENROLLING_BY_INVITATIONThis study tests whether theophylline, a drug used for asthma, can help children and young adults with pseudohypoparathyroidism—a rare genetic condition causing early obesity, hormone problems, and short stature. Researchers will check for weight loss, better blood sugar control,…
Phase: PHASE2 • Sponsor: Jaclyn Tamaroff • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Botox shot during prostate op eases overactive bladder
Disease control OngoingThis study looked at 70 men with an enlarged prostate and overactive bladder symptoms. Some received a Botox injection into the prostate during surgery, while others took standard medication after surgery. The Botox group showed better symptom scores at 12 weeks, suggesting a pot…
Sponsor: Taksim Egitim ve Arastirma Hastanesi • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo aims to treat bladder cancer without chemo
Disease control OngoingThis Phase 2 trial tests two new immunotherapy drugs, tobemstomig alone or with tiragolumab, against the standard drug atezolizumab. It includes 204 people with advanced bladder cancer who cannot have platinum chemotherapy. The main goal is to check safety and side effects.
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Old asthma drug could help kids with rare bone and hormone disorder
Disease control OngoingThis phase 2 trial tests theophylline, a drug used for asthma, in 34 children aged 2 to 12 with pseudohypoparathyroidism, a genetic condition causing obesity, short stature, and hormone resistance. The study aims to see if theophylline can help with weight loss, slow bone growth …
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to keep bladder cancer at bay after chemo
Disease control OngoingThis phase 2 trial tests whether adding avelumab (an immunotherapy) to another anti-cancer drug (sacituzumab govitecan) can help prevent advanced bladder cancer from growing after initial chemotherapy. About 256 participants with locally advanced or metastatic urothelial carcinom…
Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cholesterol drug paired with immunotherapy shows promise for tough kidney cancer
Disease control OngoingThis phase 2 trial tests whether adding evolocumab (a cholesterol-lowering drug) to nivolumab (an immunotherapy) can help control metastatic kidney cancer that has not responded to prior treatments. Only 10 participants are enrolled, and the main goal is to check safety and side …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Breathing in a cancer fighter: inhaled IL-2 trial targets lung tumors
Disease control OngoingThis study tests an inhaled form of interleukin-2 (IL-2), a protein that boosts the immune system, in people whose cancer has spread to the lungs. The goal is to find the best dose and see if it can shrink lung tumors. About 70 adults with cancers like melanoma, sarcoma, or kidne…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill shows promise for Tough-to-Treat bladder cancer
Disease control OngoingThis study tests a pill called erdafitinib in 20 people whose non-muscle invasive bladder cancer has returned after standard treatments like BCG. All participants have a specific change in the FGFR3 gene, which the drug targets. They take the pill for about a month before their s…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a Heart-to-Heart talk keep dialysis patients on track?
Disease control OngoingThis study tests whether motivational interviewing, a counseling style that encourages patients to find their own reasons for change, can help African American adults on hemodialysis attend all their sessions. 176 participants will either receive the coaching or standard care, an…
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a heart drug boost bladder cancer treatment?
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests whether adding the blood pressure drug propranolol to standard immunotherapy and chemotherapy can help shrink bladder cancer that has spread to lymph nodes before surgery. The study enrolls 12 patients and primarily checks for safety and side effects.…
Phase: PHASE1 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail shows promise against Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…
Phase: PHASE2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control OngoingThis Phase 3 trial tests sparsentan, a new drug, against irbesartan (a standard treatment) in 406 adults with IgA nephropathy, a kidney disease. The goal is to see if sparsentan better protects kidney function over about 2 years. Participants must have significant protein in thei…
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New procedure aims to shrink kidney tumors without surgery
Disease control OngoingThis study tests a minimally invasive procedure that blocks blood flow to kidney angiomyolipomas (non-cancerous tumors). The goal is to shrink the tumors and stop bleeding while preserving kidney function. Researchers will follow 50 patients for one year to check safety and effec…
Sponsor: Botkin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can freezing ovarian tissue help girls have babies later?
Disease control OngoingThis study offers girls from birth to age 17 the chance to freeze their ovarian tissue before medical treatments that could harm their fertility, such as chemotherapy or radiation. The tissue is removed surgically and stored. Later, if they want to have children, the tissue can b…
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug combo shows promise in shrinking advanced kidney tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks before their operation. The go…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Kidney transplant virus filter trial pulled before start
Disease control TerminatedThis study aimed to see if a special blood filter (Seraph 100) could reduce BK virus levels in kidney transplant patients with high viral loads. It planned to enroll adults with a BK virus level of 10,000 IU/mL or higher who already had dialysis access. However, the trial was wit…
Phase: NA • Sponsor: ExThera Medical Europe BV • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Immunotherapy duo takes on advanced bladder cancer in global trial
Disease control OngoingThis study tested whether two immunotherapy drugs (durvalumab and tremelimumab) work better than standard chemotherapy for people with advanced bladder cancer that has spread (stage IV). Over 1,100 participants received either the drug combination, durvalumab alone, or chemo. The…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Simple dialysis tweak could save thousands of lives
Disease control OngoingThis study looks at whether adding more magnesium to the fluid used during dialysis can help people with kidney failure live longer and have fewer heart-related hospital stays. Many dialysis patients have low magnesium, which can lead to muscle cramps and heart issues. The trial …
Phase: NA • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Heat and radiation team up to fight spine cancer
Disease control OngoingThis study tests whether combining two treatments—thermal ablation (using heat to destroy tumor cells) and stereotactic radiosurgery (precise, high-dose radiation)—can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with vari…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Could a tropical berry boost immunotherapy for kidney cancer?
Disease control OngoingThis early-phase trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the co…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy combo shows promise in bladder cancer battle
Disease control OngoingThis study tests whether adding immunotherapy drugs (nivolumab, with or without BMS-986205) to standard chemotherapy before and after bladder cancer surgery helps more people achieve a complete response and live longer without the cancer returning. About 855 adults with muscle-in…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Radiation may replace drugs for some kidney cancer patients
Disease control TerminatedThis phase 2 trial tests whether high-precision radiation (SBRT) can control kidney cancer that has spread to a few spots in the body. The goal is to see if radiation alone can delay or replace the need for systemic drug therapy. The study involves 123 participants and includes b…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could estrogen shield transplanted kidneys?
Disease control OngoingThis study tests whether giving estrogen through a vein during kidney transplant surgery can reduce damage to the new kidney. It includes 30 women who need dialysis and are getting a kidney from a deceased donor. The goal is to see if estrogen helps the kidney work better right a…
Phase: PHASE1, PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for kidney disease patients: finerenone trial aims to reduce protein leakage
Disease control ENROLLING_BY_INVITATIONThis study tests whether the drug finerenone can lower protein levels in the urine of people with chronic kidney disease who are not taking certain blood pressure medications. About 180 adults will receive either finerenone or a placebo for 6 months. The goal is to see if fineren…
Phase: PHASE3 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can surgery stop kidney cancer in its tracks?
Disease control OngoingThis study looks at how well surgery works for people with kidney cancer that has spread to other parts of the body. About 86 patients will have the cancer removed by a surgeon. The goal is to see if this surgery helps them live longer without the cancer coming back.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo therapy targets rare, aggressive kidney cancer
Disease control OngoingThis study tests whether two immunotherapy drugs, nivolumab and relatlimab, can shrink or control a rare and aggressive kidney cancer called renal medullary carcinoma (RMC). The trial includes 30 adults whose cancer has spread or cannot be removed by surgery. The goal is to see h…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo therapy shows promise in bladder cancer fight
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will receive either the combination or BCG alon…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Cancer cocktail: new combo aims to tame tough tumors
Disease control OngoingThis early-phase trial tests a combination of three drugs—bortezomib, gemcitabine, and doxorubicin—in people with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the highest safe dose of the two chemotherapy drugs when …
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Bacteria bombs target stubborn tumors in new cancer combo trial
Disease control OngoingThis study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells f…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for rare kidney cancer: targeted drug savolitinib faces off against standard therapy
Disease control OngoingThis phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Bladder-Sparing chemo trial targets genetic weakness in cancer
Disease control OngoingThis phase II trial tests a combination of two chemotherapy drugs, gemcitabine and cisplatin, in people with muscle-invasive bladder cancer whose tumors have specific DNA repair gene changes (DDR alterations). The goal is to see if these patients can avoid bladder removal surgery…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Gene therapy for rare blood disease passes 15-Year safety watch
Disease control OngoingThis study follows 9 people with Fanconi Anemia who already received a gene therapy that adds a working FANCA gene to their blood stem cells. Researchers will check their health and blood counts for 15 years to see if the treatment remains safe and keeps working. No new treatment…
Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New bladder cancer device offered to patients with no other options
Disease control APPROVED_FOR_MARKETINGThis program gives patients with high-risk non-muscle invasive bladder cancer access to TAR-200 before it is officially approved. TAR-200 is a device placed into the bladder that releases medication over time. It is for patients who have tried all other treatments and cannot join…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New pill shows promise for rare kidney cancer in VHL patients
Disease control OngoingThis phase 2 trial is testing a daily pill called belzutifan in 50 people with VHL disease who have kidney cancer. The goal is to see if the drug can shrink tumors. Researchers are also monitoring how long any tumor shrinkage lasts and checking for side effects.
Phase: PHASE2 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to shrink metastatic kidney tumors
Disease control OngoingThis study tests whether adding entinostat to high-dose aldesleukin (interleukin-2) can help shrink tumors in people with metastatic kidney cancer. About 47 adults with clear cell renal cell carcinoma that has spread will receive both drugs. The goal is to find the safest dose an…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a malaria drug help fight cancer? early trial tests new combo
Disease control OngoingThis early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
40 VA hospitals test cheap drug to save kidneys in diabetes
Disease control OngoingThis study tests whether pentoxifylline, a medicine used since 1984 for leg blood vessel problems, can slow kidney damage and delay death in people with diabetic kidney disease. About 2,376 participants with type-2 diabetes and moderate-to-severe kidney decline are being followed…
Phase: PHASE4 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New registry to see if freezing or burning kidney tumors works Long-Term
Disease control TerminatedThis registry follows 750 patients with small kidney tumors who are not good candidates for surgery. They receive either cryotherapy (freezing) or radiofrequency ablation (heating) to destroy the tumor. Researchers will track survival, kidney function, and complications over time…
Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New baby pee trick could end messy urine bags in ER
Diagnosis OngoingThis study tests a bladder stimulation technique (gentle lower back massage and lower abdomen tapping) to collect urine from infants under 6 months in the emergency department. The goal is to see if this method gets cleaner samples faster than the usual adhesive bag. 124 infants …
Phase: NA • Sponsor: Istanbul Medeniyet University • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Bladder ultrasound may predict treatment success in kids with bedwetting
Diagnosis OngoingThis study looks at whether measuring bladder wall thickness with an ultrasound can help predict treatment response in children aged 5-17 with lower urinary tract problems or bedwetting. Researchers will compare bladder wall measurements between the two groups and see if thicknes…
Sponsor: Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Kidney injury detection tool for heart surgery patients pulled before testing
Diagnosis TerminatedThis study aimed to see if an ultrasound score called VEXUS could help detect acute kidney injury in adults after heart surgery. About 20% of patients develop this complication, which raises the risk of death. However, the study was withdrawn before enrolling any participants, so…
Sponsor: University Hospital, Rouen • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New scan aims to catch kidney cancer spread that others miss
Diagnosis TerminatedThis study planned to test a special PET-CT scan (68Ga-PSMA) in people newly diagnosed with advanced kidney cancer. The goal was to see if it could find small cancer spots that standard scans miss. However, the trial was withdrawn before any patients were enrolled, so no results …
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New imaging tracer could spot kidney cancer without a needle
Diagnosis NO_LONGER_AVAILABLEThis program gives patients with kidney masses access to a radioactive tracer called 89Zr-DFO-girentuximab, which is used with a PET/CT scan to detect clear cell renal cell carcinoma (a common kidney cancer) without surgery. The tracer attaches to a protein (CAIX) often found on …
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Simple urine test may spot kidney damage in kids after heart surgery before standard methods
Diagnosis OngoingThis study looks at whether a substance called UDP-glucose in urine can help doctors find kidney injury earlier in children after heart surgery. Current tests often miss early signs, delaying treatment. About 305 children under 8 years old having heart surgery will provide urine …
Sponsor: Boston Children's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
Can a single CT scan replace two tests for bladder cancer?
Diagnosis OngoingThis study compares two imaging techniques—CT urography (CTU) and intravenous urography (IVU)—in 133 bladder cancer patients to see if CTU alone can effectively monitor the disease. Researchers want to determine if CTU provides clear enough images of the urinary tract to replace …
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC
-
Could a simple supplement shield bones and kidneys from common heartburn drugs?
Prevention TerminatedThis trial investigates whether a daily effervescent supplement containing calcium, magnesium, and citrate can prevent bone loss, magnesium deficiency, and kidney damage in adults who take proton pump inhibitors (PPIs) long-term for conditions like heartburn or GERD. Participants…
Phase: PHASE3 • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Liver transplant patients may dodge kidney failure with simple drug infusion
Prevention OngoingThis study tests whether giving a drug called angiotensin 2 during liver transplant surgery can prevent acute kidney injury, a common and serious complication. About 30 adults with end-stage liver disease will be randomly assigned to receive either the drug plus standard care or …
Phase: PHASE4 • Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 13:08 UTC
-
Heart surgery patients may get kidney protection from old iron drug
Prevention OngoingThis study tests whether a drug called deferoxamine can prevent acute kidney injury in adults undergoing heart surgery. The drug works by removing excess iron, which is thought to damage the kidneys during surgery. About 320 participants will receive either the drug or a placebo …
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Brain radiation may stop cancer spread in rare bladder cancer
Prevention OngoingThis study tests whether whole brain radiation can lower the chance of brain tumors in people with small cell carcinoma of the urinary tract (including the bladder). The 31 participants have already had chemotherapy and responded well. They receive radiation to the brain for 3 we…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Could a common drug keep bladder cancer away?
Prevention OngoingThis phase II trial tests whether a low-dose version of the drug rapamycin, called eRapa, can prevent bladder cancer from coming back in people who have already been treated for non-muscle invasive bladder cancer. About 166 participants will take eRapa or a placebo daily for one …
Phase: PHASE2 • Sponsor: Robert Svatek • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Ear zap may shield kidneys during heart surgery
Prevention ENROLLING_BY_INVITATIONThis study tests a non-invasive ear stimulation technique (taVNS) to prevent acute kidney injury in 152 adults having heart surgery with a heart-lung machine. Half receive real stimulation before and after surgery; the other half get a sham. The main goal is to see if fewer peopl…
Phase: NA • Sponsor: Sir Run Run Shaw Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:36 UTC
-
COVID-19 prevention study in kidney patients pulled before it began
Prevention TerminatedThis study aimed to see if hydroxychloroquine could prevent COVID-19 hospitalizations in adults on dialysis for kidney failure. It was designed as a randomized trial but was withdrawn before enrolling any participants. No results are available.
Phase: PHASE4 • Sponsor: Nicholas Carlson • Aim: Prevention
Last updated Jun 27, 2026 12:35 UTC
-
Computer alert aims to stop kidney damage before it starts
Prevention OngoingThis study tests whether a computer program that spots early signs of acute kidney injury can improve patient care. Hospitalized adults at risk are randomly assigned to get an early kidney specialist visit or standard care. The goal is to see if early specialist advice can preven…
Phase: NA • Sponsor: University of Chicago • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Can a TB vaccine stop bladder cancer from coming back?
Prevention OngoingThis Phase 3 trial tests whether a therapeutic BCG vaccine, given directly into the bladder, can prevent non-muscle-invasive bladder cancer from returning after surgery. About 439 adults with intermediate- or high-risk cancer are participating. The study compares BCG to an active…
Phase: PHASE3 • Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
Laser and kegels: new combo tackles leaky bladder
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether adding high-frequency laser therapy to pelvic floor muscle training helps women with stress urinary incontinence. Thirty-six women will be split into three groups: exercises alone, exercises plus real laser, or exercises plus a fake laser. Researchers …
Phase: NA • Sponsor: Necmettin Erbakan University • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Pill or needle? new study tests two treatments for bladder leaks
Symptom relief OngoingThis study compares two treatments for women with urgency urinary incontinence (sudden, strong urges to urinate that lead to leakage). Participants will be randomly assigned to take an oral beta-agonist pill or receive Botox injections into the bladder. The main goals are to see …
Phase: PHASE4 • Sponsor: Women and Infants Hospital of Rhode Island • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Testosterone shots aim to strengthen pelvic floor in older women
Symptom relief OngoingThis pilot study tests whether weekly testosterone injections can increase pelvic floor muscle size and improve stress urinary incontinence in women aged 60 and older. The trial involves 30 participants and uses MRI to measure muscle changes. It is a small, early-stage proof-of-c…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New device aims to stop urgent bathroom trips
Symptom relief OngoingThis study tests the Revi System, a device that may help people with sudden, strong urges to urinate that cause leaking. About 150 adults who have had this problem for at least 6 months will either get the active device or an inactive version. The goal is to see if the active dev…
Phase: NA • Sponsor: BlueWind Medical • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could special glasses fight dialysis fatigue?
Symptom relief OngoingThis study tests whether wearing bright light glasses during dialysis can reduce severe fatigue in people with end-stage kidney disease. Sixty adults on hemodialysis will use the glasses for one hour, three times a week, for four weeks. The goal is to see if this simple, non-drug…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Nurse calls from home: a new way to manage kidney disease?
Symptom relief OngoingThis study tests whether a 9-week tele-nursing program—including education, phone or online check-ins, and counseling—can improve quality of life and health outcomes for people with stage 3 or 4 chronic kidney disease who are not yet on dialysis. Researchers will compare 66 parti…
Phase: NA • Sponsor: Istanbul University - Cerrahpasa • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could a magnetic helmet ease bladder pain? new study investigates
Symptom relief OngoingThis study tests whether a non-invasive magnetic brain stimulation technique, called rTMS, can reduce pain in women with interstitial cystitis or bladder pain syndrome. The treatment targets brain areas that control pelvic floor muscles, aiming to lower pain by improving how the …
Phase: NA • Sponsor: University of Southern California • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can a new therapy help cancer patients kick the habit?
Symptom relief OngoingThis study compares a new counseling approach called Acceptance and Commitment Therapy (ACT) with standard counseling to help people with head and neck, lung, breast, gastrointestinal, or genitourinary cancer stop smoking. About 51 adults who smoke at least one cigarette per day …
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New laser mode may speed up kidney stone removal
Symptom relief OngoingThis study compares two laser methods for breaking up kidney and ureteral stones during surgery. One method uses standard laser pulses, the other uses a newer 'Moses 2.0' pulse mode. Researchers want to see if the newer mode reduces surgery time and improves stone clearance. Abou…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Sound waves could push kidney stones out without surgery
Symptom relief OngoingThis study tests a device that uses focused ultrasound to gently push kidney stones, helping them pass or relieving pain. Researchers are enrolling 172 people with kidney stones, including those waiting for treatment or recently treated. The goal is to see if the ultrasound can m…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New program aims to reduce complications after bladder cancer surgery
Symptom relief TerminatedThis study tested a program to help bladder cancer patients recover better after bladder removal surgery. The program included extra monitoring and support before, during, and after the operation to catch problems early. The goal was to reduce complications within 90 days after s…
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Can online pelvic floor training match in-person sessions for incontinence relief?
Symptom relief OngoingThis study compares two ways of doing pelvic floor muscle training for postmenopausal women with urinary incontinence: one group does the exercises online with a physiotherapist, and the other does them in person. Both groups follow the same exercise plan. The goal is to see if t…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Could a headband zap away dialysis pain?
Symptom relief OngoingThis study tests a small, battery-powered headband that delivers a gentle electrical pulse to the scalp to help reduce chronic pain in people with end-stage kidney disease who are on dialysis. About 125 adults will use the device at home and report their pain levels. The goal is …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Sleep training plus bladder pill may cut nighttime bathroom trips in older women
Symptom relief OngoingThis study looks at whether adding a brief sleep program to standard bladder medication can reduce urgent leaks and nighttime urination in women aged 60 and older. About 120 women with frequent urgency incontinence and nocturia will receive either medication alone or medication p…
Phase: PHASE4 • Sponsor: Shachi Tyagi • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New hope for kidney stone patients: safer pain relief after surgery?
Symptom relief OngoingThis study compares two drugs—methocarbamol and oxybutynin—to see which works better for pain and discomfort caused by a ureteral stent placed after kidney stone surgery. About 126 adults aged 18 to 80 who have the surgery will take one of the study drugs along with standard pain…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Can a phone app ease kidney disease stress?
Symptom relief ENROLLING_BY_INVITATIONThis study tests a digital mindfulness app called Calm Health in 26 adults with chronic kidney disease. Participants use the app for 6 weeks while wearing a wrist sensor to track sleep, activity, and heart rate. The goal is to see if the app is easy to use and if it helps reduce …
Phase: NA • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Can a simple surgery fix incontinence for good? new study follows patients for 2 years.
Symptom relief OngoingThis study follows 200 adults with stress or urge incontinence to see how well two surgical procedures work over two years. One surgery tightens ligaments for stress incontinence, the other for urge incontinence. Researchers will measure success by continence rates and track any …
Phase: NA • Sponsor: Alev Esercan • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Remote exercise and education program aims to boost Well-Being in older cancer patients
Symptom relief OngoingThis study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …
Phase: NA • Sponsor: Martine Puts • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Magnetic pulses may offer Drug-Free relief for bladder leakage
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether magnetic stimulation of the pelvic floor can help women with stress urinary incontinence (leaking urine when coughing, sneezing, or exercising). About 158 adult women will receive the treatment and report their symptoms using questionnaires. The goal is t…
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Can a laser fix bladder leaks? new study tests vaginal treatment for urine control
Symptom relief OngoingThis study tests whether a laser applied to the vagina can help women with stress urinary incontinence (leaking urine when coughing, sneezing, or exercising). About 144 women will receive the laser treatment and be followed for 6 months. The main goal is to see if the treatment r…
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Shorter stent time may ease Post-Surgery discomfort
Symptom relief OngoingThis study looks at whether removing a ureteral stent 3 days after kidney stone surgery is as safe and less bothersome than the usual 7 days. About 172 adults having simple stone treatment will be randomly assigned to either 3 or 7 days of stent placement. The goal is to see if a…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Simple breathing trick boosts kegel results for bladder leakage
Symptom relief OngoingThis study looks at whether adding diaphragmatic breathing to standard Kegel exercises can improve pelvic floor muscle strength and quality of life in women who have had multiple pregnancies and suffer from stress urinary incontinence (leaking urine when coughing, sneezing, or ex…
Phase: NA • Sponsor: Lahore University of Biological and Applied Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
New flexible scope aims to zap kidney stones in one go
Symptom relief OngoingThis study tests a new surgical technique for removing large kidney stones (2 cm or bigger). Doctors will use a flexible scope and a special suction tube to break up and remove the stones. The goal is to see if this method is safe and can clear all stones in one procedure. Thirty…
Phase: NA • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Mini GPS in a needle could help doctors hit hidden tumors
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find tumors that are hard to see on CT scans. About 3,900 adults with certain cancers or growths will have their biopsy or ablation procedure done using this smart needle. The g…
Phase: NA • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Kidney tumor ablation: does it destroy cancer and boost well-being?
Knowledge-focused OngoingThis study tracks people who have had or will have a procedure called ablation to destroy kidney tumors. Researchers want to see how effective the procedure is and whether it improves patients' quality of life. Participants fill out questionnaires about their health and well-bein…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
AI-Guided radiation may shield ovaries in young cancer patients
Knowledge-focused OngoingThis study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Why kidney patients feel so tired: muscle fatigue under the microscope
Knowledge-focused TerminatedThis study investigates why people with advanced chronic kidney disease (not yet on dialysis) often feel deep fatigue. Researchers will measure muscle strength and fatigue using simple tests like hand grip and walking speed. The goal is to understand how kidney disease affects ne…
Sponsor: Centre Hospitalier le Mans • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Wheat germ supplement studied for immune boost in advanced cancer
Knowledge-focused TerminatedThis study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
150,000 patients tracked: does finerenone protect hearts in kidney disease and diabetes?
Knowledge-focused OngoingThis observational study follows 150,000 people with chronic kidney disease and type 2 diabetes to see how finerenone (Kerendia) works in everyday medical care. Researchers will compare those taking finerenone to those not taking it, looking at rates of heart attacks and heart fa…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Kidney cancer drug use under the microscope in belgian study
Knowledge-focused OngoingThis study tracks how 150 patients in Belgium use the drug cabozantinib (Cabometyx), alone or with nivolumab, for advanced or metastatic kidney cancer. It looks at real-world dosing, treatment changes, and quality of life. The goal is to understand how these treatments are actual…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
No more catheters? new device aims to make bladder testing easier
Knowledge-focused OngoingThis study is testing a new wireless device called the Glean Urodynamics System (GUS) that monitors bladder pressure without a catheter. It involves 28 adult women with urinary symptoms. Participants will use the device during standard tests and at home. The goal is to see if GUS…
Phase: NA • Sponsor: Bright Uro • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Kidney cancer drug combo under the microscope in Real-World study
Knowledge-focused OngoingThis study observes 224 adults with advanced or metastatic kidney cancer who are taking cabozantinib alone or with nivolumab as their first treatment. Researchers track how often doses are reduced, paused, or stopped due to side effects in everyday medical practice. The goal is t…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive family study hunts for kidney disease genes in diabetes
Knowledge-focused OngoingThis large study is looking at the genes of over 9,000 people with diabetes and kidney disease, along with their family members. The goal is to find which genes make some people more likely to get diabetic kidney disease. By understanding the genetic roots, researchers hope to de…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive korean study maps the overlap of heart, kidney, and metabolic diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study examines health data from about 800,000 Korean adults to see how often conditions like obesity, type 2 diabetes, heart disease, chronic kidney disease, and fatty liver occur together. Researchers will analyze national survey and insurance records from 2013 to 2023. No …
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study watches how kidney drug works in real life
Knowledge-focused OngoingThis observational study follows over 4,600 adults with chronic kidney disease and type 2 diabetes who are starting finerenone, a drug that helps slow kidney damage. Researchers will collect data from routine doctor visits over 12 months to understand why doctors prescribe it, ho…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive kidney study aims to uncover hidden heart risks
Knowledge-focused OngoingThis long-term study follows over 5,000 people with chronic kidney disease to learn how the condition affects the heart and blood vessels. Researchers are tracking kidney function, heart events like heart attacks and strokes, and various risk factors. The goal is to find better w…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive UK study tracks cancer after organ transplants
Knowledge-focused OngoingThis study looks at why people who have had an organ transplant are more likely to get cancer. Researchers will combine existing health records from over 85,000 transplant patients in England to track cancer cases and deaths. The goal is to better understand risks and improve car…
Sponsor: University of Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New study aims to close kidney transplant gap for minorities
Knowledge-focused OngoingHispanic/Latino and American Indian patients are less likely to get kidney transplants, even though they have higher rates of kidney failure. This study compares two methods to help them complete the transplant evaluation process: a fast-track evaluation done in one day or within…
Phase: NA • Sponsor: University of New Mexico • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Kidney dialysis drug study pulled before it started
Knowledge-focused TerminatedThis study was designed to see how a low dose of bevacizumab (Avastin) behaves in the body and whether it safely lowers a certain protein (VEGF-A) in people with kidney failure on dialysis. The goal was to gather information for a future trial on preventing dialysis access failur…
Phase: EARLY_PHASE1 • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Massive study aims to predict and prevent kidney failure in ICU patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows thousands of critically ill adults in intensive care units across China to better understand acute kidney injury (AKI), a common and dangerous complication. Researchers will collect medical data, images, and biological samples to build a large database. The goa…
Sponsor: Beijing Chao Yang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Nerve-Calming amino acid may cut heart risk in kidney disease
Knowledge-focused OngoingThis study investigates whether a single infusion of L-arginine, an amino acid, can reduce abnormally high sympathetic nerve activity in people with chronic kidney disease (CKD). High nerve activity is linked to increased cardiovascular risk in CKD patients. Researchers will meas…
Phase: PHASE4 • Sponsor: The University of Texas at Arlington • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
CT 'Fingerprint' may predict kidney stone smash success in kids
Knowledge-focused OngoingThis study looks at whether a measurement called the stone heterogeneity index (SHI), taken from a CT scan, can predict how well shock wave lithotripsy (SWL) breaks up upper urinary tract stones in children aged 1 to 18. Researchers will follow 286 children for three months after…
Sponsor: Mansoura University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Ultrasound for all: 9,000-Patient trial tests quicker hospital stays
Knowledge-focused OngoingThis study looks at whether using a simple bedside ultrasound exam on all hospitalized patients can shorten their hospital stay. Researchers will check the heart, kidneys, liver, and lungs for common problems. The goal is to see if this routine check helps doctors make faster dec…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study checks if past drug still protects kidneys years later
Knowledge-focused TerminatedThis study looks at American Indians with type 2 diabetes who had early kidney disease and took a drug called losartan years ago. Researchers want to see if the benefits of that treatment still help protect their kidneys today. About 141 people who were in the earlier study or th…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study seeks better ways to spot malnutrition in dialysis patients
Knowledge-focused OngoingThis study observes 69 adults with chronic kidney disease who are on hemodialysis. Researchers want to find the best way to diagnose malnutrition using the GLIM criteria and other tools. The goal is to see which methods best predict declines in quality of life, muscle strength, a…
Sponsor: Umeå University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to see if patient diaries match insurance data
Knowledge-focused TerminatedThis study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Real-world finerenone use in indian kidney and diabetes patients under review
Knowledge-focused OngoingThis study reviews medical records of 1200 Indian adults with chronic kidney disease and type 2 diabetes who started finerenone between August 2022 and April 2024. Researchers will analyze how doctors prescribed the drug, dose changes, and lab results like kidney function and pot…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists track families to uncover Cancer's hidden causes
Knowledge-focused OngoingThis study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Which catheter method reduces Post-Birth bladder problems?
Knowledge-focused OngoingThis study looks at 300 pregnant women who have an epidural during labor. It compares leaving a catheter in place all the time versus inserting and removing it every few hours. The goal is to see which method leads to fewer bladder issues and infections after giving birth.
Phase: NA • Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Dialysis access anesthesia study pulled before starting
Knowledge-focused TerminatedThis study was designed to see if different types of anesthesia could help a surgically created blood vessel connection (called a fistula) work better for dialysis patients. The plan was to compare three methods: a nerve block in the armpit, a nerve block in the neck, and local a…
Phase: NA • Sponsor: McMaster University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New study aims to give kidney patients real choices beyond dialysis
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests two ways to help older adults with kidney failure make informed choices about their care. One approach offers education and decision aids; the other adds a supportive care program for those who choose non-dialysis options. Researchers will compare how many patien…
Phase: NA • Sponsor: George Washington University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Scientists hunt for genes behind kidney disease
Knowledge-focused OngoingThis study aims to find the genetic causes of kidney diseases like FSGS and nephrotic syndrome. Researchers will collect saliva and urine samples from up to 2,050 participants, including patients and their family members, as well as healthy volunteers. The goal is to understand w…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New screening tool aims to catch hidden need for palliative care in hospitals
Knowledge-focused OngoingThis study tests a questionnaire called NECPAL to see if it can spot patients with serious long-term illnesses like cancer, heart failure, or kidney disease who might benefit from palliative care. Researchers will check 200 adults in the hospital or day clinic to see how many are…
Sponsor: Infanta Leonor University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Ground-Level vision test could help retinitis pigmentosa patients walk better
Knowledge-focused TerminatedThis study was designed to see if a new method of measuring the visual field—by projecting vision zones on the ground—helps people with retinitis pigmentosa understand their remaining sight and improve their walking rehabilitation. The trial was withdrawn before enrolling any par…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Vitamin C's hidden role in kidney stones revealed
Knowledge-focused OngoingThis study looks at how vitamin C (ascorbic acid) turns into oxalate, a key component of kidney stones. Researchers will give a special labeled vitamin C to 136 adults—both with and without kidney stones—and measure how much oxalate ends up in their urine. The goal is to understa…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Hidden killers in controlled hypertension: study probes why blood pressure meds aren't enough
Knowledge-focused OngoingThis study combines data from over 2,500 people with treated and controlled high blood pressure to understand why some still die from heart attacks, strokes, or kidney failure. Researchers are looking beyond blood pressure numbers to find other factors that might predict these fa…
Sponsor: DejthidaNathaphong • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Spinach smoothie study reveals immune cell energy secrets
Knowledge-focused OngoingThis study looks at how oxalate, a compound found in spinach, affects the energy use of white blood cells in healthy adults. Researchers will give participants a spinach smoothie and measure changes in immune cell function over five hours. The goal is to better understand how die…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Heart attack survivors' kidneys under microscope in massive study
Knowledge-focused OngoingThis study examines how different hospital treatments—sedation, temperature control, and blood pressure management—after a cardiac arrest impact kidney function. Researchers will follow 3500 adults who were resuscitated from a heart attack outside the hospital. The goal is to und…
Phase: NA • Sponsor: Helsinki University Central Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Long-Term study sheds light on rare bone and hormone disorder
Knowledge-focused OngoingThis study follows 600 people with Albright hereditary osteodystrophy, a rare genetic condition affecting bones and hormones. Researchers are looking at how growth hormone treatment affects height and weight in those with a related hormone problem, and also studying thinking and …
Phase: NA • Sponsor: Connecticut Children's Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Bladder cancer study reveals how surgery changes Patients' lives
Knowledge-focused OngoingThis study follows 550 people with bladder cancer to understand how treatments like surgery affect their quality of life. Researchers want to learn what patients go through so doctors can offer better support and clearer information. The goal is to improve care, not to test a new…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Researchers track rare bone disease over years in observational study
Knowledge-focused OngoingThis study follows 23 people with tumor-induced osteomalacia (TIO), a rare condition where tumors cause weak bones. The goal is to see how well the drug burosumab works over time and to monitor any tumor changes. Participants continue their usual care, and no new treatments are g…
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Hidden kidney trouble: high blood pressure study in kazakhstan aims to find the missing cases
Knowledge-focused OngoingThis study is tracking over 1,200 adults in Kazakhstan who have high blood pressure to see how many also have signs of chronic kidney disease (CKD). Researchers will measure things like protein in urine and kidney function. The goal is to understand how often CKD goes undiagnosed…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Kidney shield: diabetes Drug's hidden powers revealed?
Knowledge-focused OngoingThis study looks at how canagliflozin (Invokana), a diabetes drug, protects the kidneys in people with type 2 diabetes. Researchers will use advanced imaging, kidney biopsies, and function tests to uncover the mechanisms. The trial involves 45 adults and aims to explain the drug'…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Healthy volunteers help unravel Kidney's role in Stone-Forming oxalate
Knowledge-focused OngoingThis study looks at how the kidneys turn a substance called glycolate into oxalate, which can form kidney stones. Fifteen healthy adults will eat a special low-oxalate diet and receive a harmless tracer to track this process. The goal is to better understand how oxalate is made i…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Researchers review Real-World use of avelumab in advanced bladder cancer
Knowledge-focused OngoingThis study reviews medical records of 360 Japanese patients with advanced bladder cancer who received avelumab as a maintenance treatment after initial chemotherapy. The goal is to understand patient characteristics, treatment patterns, and outcomes like survival and tumor respon…
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Gene study aims to boost kidney transplant success for african americans
Knowledge-focused OngoingThe APOLLO study looks at how variations in the APOL1 gene, common in people of African ancestry, affect kidney transplant outcomes. Researchers are testing DNA from 5,000 kidney donors and recipients to see if certain gene variants lead to faster kidney failure or harm living do…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Real-World data sought on nivolumab for bladder cancer after surgery
Knowledge-focused OngoingThis study observes 400 Japanese patients with muscle-invasive urothelial carcinoma who received nivolumab after surgery to remove their cancer. Researchers will track how long patients stay cancer-free, side effects, and how the drug is actually used in clinics. The goal is to s…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Can a diabetes drug help dialysis patients? small study aims to find out
Knowledge-focused OngoingThis early study is testing whether the diabetes and heart failure drug empagliflozin (Jardiance) is safe for people on dialysis for kidney failure. The drug is already approved for other uses but has not been studied in dialysis patients. Researchers will give 24 participants ei…
Phase: PHASE1, PHASE2 • Sponsor: University of Mississippi Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Kidney function may affect hepatitis b drug levels
Knowledge-focused OngoingThis study gives a single dose of bepirovirsen to 32 adults with hepatitis B, some with kidney disease and some healthy. Researchers measure how much drug gets into the blood and how long it stays. The goal is to see if kidney problems change drug levels, which could affect futur…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New scan technique may reveal early if kidney cancer drugs are effective
Knowledge-focused OngoingThis study tests whether a special type of CT scan (DCE-CT) can help doctors see if targeted therapy drugs for advanced kidney cancer are working. About 120 adults with metastatic renal cell carcinoma will get these scans before and shortly after starting treatment. The goal is t…
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Kidney transplant patients' immune response to common virus tracked after drug switch
Knowledge-focused OngoingThis study follows 28 kidney transplant recipients who are switching from one anti-rejection drug (anticalcineurin) to another (belatacept). Researchers want to see how this change affects the immune system's ability to fight the common CMV virus. Participants will have blood tes…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New study probes why kidney disease still strikes in type 1 diabetes
Knowledge-focused OngoingThis study looks at why up to 40% of people with type 1 diabetes develop kidney disease, even with better blood sugar control. Researchers will use kidney biopsies and advanced imaging in 100 adults to find hidden risk factors like insulin resistance and inflammation. The goal is…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Scientists dig into tumor DNA to crack immunotherapy resistance
Knowledge-focused OngoingThis study examines stored tumor samples from 15 people with kidney or bladder cancer who initially responded to immune checkpoint therapy but later developed new tumors. Researchers will compare the genetic and tissue features of the original and new tumors to understand how the…
Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Gene therapy safety check: 400 cancer patients monitored for years
Knowledge-focused ENROLLING_BY_INVITATIONThis study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Blood test may spot hidden heart risk in kidney patients
Knowledge-focused OngoingThis study looks at whether low levels of pyrophosphate, a natural substance that prevents mineral buildup, can predict artery hardening in people with moderate chronic kidney disease. Researchers will measure pyrophosphate in blood samples from 242 patients and track artery chan…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists map hidden blood vessels to solve leakage mystery
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how blood flow to the urethra relates to bladder control. Researchers will use special ultrasound imaging in 70 women—35 with stress urinary incontinence and 35 without—to compare blood supply and pressure measurements. The goal is to better understand what ca…
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Needle-Sized device could reveal which bladder cancer drug works best
Knowledge-focused ENROLLING_BY_INVITATIONThis early-stage study tests a tiny implantable device that releases very small amounts of several cancer drugs directly into bladder tumors. The goal is to see if the device is safe and can help doctors figure out which drugs kill the tumor best. Only 18 people with muscle-invas…
Phase: EARLY_PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New breathing technique tested in robotic cancer surgery
Knowledge-focused TerminatedThis study aimed to compare a newer breathing machine method (APRV) with the standard method (CMV) during anesthesia for robotic gynecologic or genitourinary cancer surgery. The goal was to find the best settings to help patients' lungs work well during the procedure. However, th…
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Massive study reveals best Second-Line diabetes meds for heart and kidney protection
Knowledge-focused OngoingThis study looks at health records from over 780,000 people with type 2 diabetes to compare four common second-line medications: SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The goal is to see which drug class is most effective at preventing hea…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Why are young people getting cancer? a massive study aims to find out.
Knowledge-focused TerminatedThis research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Can a Tumor's 'Neighborhood' predict drug success?
Knowledge-focused OngoingThis study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Second thoughts: study probes regret after kidney transplant
Knowledge-focused OngoingThis study looks at whether people who received a kidney transplant later regret their choice. Researchers will survey 250 patients one year after their transplant to measure feelings of regret and quality of life. The goal is to understand how common regret is and help doctors s…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Scientists map hidden tumor diversity in rare kidney cancer
Knowledge-focused OngoingThis study aims to understand why kidney tumors in people with VHL syndrome can be different from each other. Researchers will use advanced imaging, multiple biopsies, and lab-grown tumor models to map these differences. The goal is to learn more about the disease, not to test a …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Hidden costs of cancer surgery: new study tracks financial burden after robotic procedures
Knowledge-focused OngoingThis study looks at how robotic surgery for prostate, bladder, or kidney cancer affects patients' finances. Researchers will ask 120 people who had surgery in the last year to fill out questionnaires about their medical costs, travel expenses, and support needs. The goal is to un…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Dialysis vein mystery: researchers hunt for clues to prevent blockages
Knowledge-focused OngoingThis study follows 96 people with end-stage kidney disease who need a brachiocephalic fistula for dialysis. Researchers collect data from exams, blood tests, and imaging to track changes in the vein over time. The goal is to learn what causes cephalic arch stenosis, a common narr…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
AI alerts for surgery patients: study pulled before it began
Knowledge-focused TerminatedThis study planned to test whether giving doctors machine-learning alerts about patient risks after surgery could reduce serious complications like kidney injury or unplanned ICU stays. It was designed for high-risk patients, but the study was withdrawn before enrolling anyone, s…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Can a website make your doctor visit faster and clearer?
Knowledge-focused OngoingThis study tests a web-based tool called WellPrept that gives patients clear information before their urology procedures. Researchers want to see if it helps patients feel more confident and understand their condition better, and if it shortens clinic visits. About 300 men and wo…
Phase: NA • Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New MRI scan could revolutionize kidney disease monitoring
Knowledge-focused OngoingThis study is testing whether a detailed MRI scan can provide better information about chronic kidney disease (CKD) than standard tests. Researchers will scan 486 adults with CKD and track their health over time to see if the MRI can predict which patients will get worse. The goa…
Sponsor: University Hospitals of Derby and Burton NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New kidney drug tested for safety with statins and blood thinners
Knowledge-focused TerminatedThis study was designed to see how a new experimental drug for chronic kidney disease, nurandociguat, affects the way the body processes two common medicines: rosuvastatin (a cholesterol drug) and dabigatran (a blood thinner). Healthy adults would have taken these drugs alone and…
Phase: PHASE1 • Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Can weekly Check-Ins improve chemo tolerability for kidney cancer patients?
Knowledge-focused OngoingThis study explores whether having kidney cancer patients report their side effects weekly through a short survey can help doctors manage those side effects better. The surveys ask about symptoms like nausea and fatigue and are sent directly to the care team, who then follow up i…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Kidney injury study scrapped before enrolling a single patient
Knowledge-focused TerminatedThis study was designed to track the long-term health of hospitalized patients in China who develop acute kidney injury (AKI). Researchers planned to monitor kidney function decline, new heart problems, and death rates over time. However, the study was withdrawn before any partic…
Sponsor: XinLing Liang • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Major study aims to settle debate on best bladder cancer treatment
Knowledge-focused OngoingThis study compares two common treatments for recurrent non-muscle-invasive bladder cancer: medical therapy (drugs placed in the bladder) and surgery (bladder removal). Researchers will track quality of life and patient experiences in 570 adults to see which approach works better…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Scientists search for keys to unlock immune attack on rare adrenal cancer
Knowledge-focused OngoingThis study is not testing a new drug, but rather doing the early science needed to develop one. Researchers are looking for the right targets (antigens) on adrenocortical carcinoma cells and studying how the tumor suppresses the immune system. The goal is to find a way to create …
Sponsor: University of Wuerzburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New registry tracks Real-Life catheter experiences to improve bladder care
Knowledge-focused OngoingThis study is creating a large registry of 600 adults who use catheters to empty their bladder due to nerve damage or other causes. Participants will report on their satisfaction, quality of life, and any infections or complications. The goal is to gather real-world data to bette…
Sponsor: Hollister Incorporated • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New MRI technique could predict kidney cancer type and Post-Surgery outcomes
Knowledge-focused OngoingThis study uses special MRI scans to look at kidney tumors in 39 people scheduled for surgery. The goal is to see if these scans can tell whether a tumor is cancerous and what type it is, as well as predict how well the kidney will work after part of it is removed. No new treatme…
Phase: NA • Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Study aims to uncover hidden side effects of common adrenal cancer drug
Knowledge-focused OngoingThis study follows 400 people with adrenocortical carcinoma who are taking mitotane as their first treatment. The goal is to carefully record all side effects, including ones that are not well understood. By collecting this data, researchers hope to improve how side effects are m…
Sponsor: University of Wuerzburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Stanford study on Kids' bathroom habits pulled before it began
Knowledge-focused TerminatedThis study aimed to help 4th graders develop healthy bladder habits by providing education, water stations, and changes to classroom bathroom policies. Researchers planned to track bathroom use, symptom scores, and urine volume. However, the study was withdrawn before enrolling a…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Could diabetes drugs help kidney patients avoid anemia?
Knowledge-focused OngoingThis study looks at whether SGLT2 inhibitors, a type of diabetes drug, can help prevent or manage anemia in people with chronic kidney disease. Researchers will analyze data from 15,000 patients in Japan to see how these drugs affect anemia rates, treatments, and costs. The goal …
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
5,000 kidney patients enrolled in landmark registry study
Knowledge-focused OngoingThis study is creating a registry of 5,000 adults with chronic kidney disease (CKD) to collect information on their health, treatments, and outcomes. Researchers aim to understand how the disease progresses, identify risk factors, and see how well current treatments match guideli…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can new sensors improve dialysis monitoring in the ICU?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether advanced monitoring devices can accurately measure blood thickness (hematocrit) and oxygen levels during continuous dialysis in critically ill patients with acute kidney injury or end-stage kidney failure. About 30 adults in the intensive care unit wil…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can a simple breath test protect dialysis Patients' brains?
Knowledge-focused OngoingThis study looks at how kidney dialysis affects brain blood flow in 37 adults with chronic kidney failure. Researchers use a special breathing device called RespirAct to measure the brain's response to carbon dioxide before and after dialysis sessions. The goal is to find ways to…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Massive ecuador study seeks clues to diabetic kidney damage
Knowledge-focused TerminatedThis study looks at over 10,000 adults in Ecuador to understand why some people with diabetes develop kidney disease. Researchers will collect health surveys, blood and urine samples, and kidney tissue to study social, environmental, and biological factors. The goal is to find ne…
Sponsor: Universidad Estatal de Milagro • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI overlays put to the test in robotic surgery: will they help or hinder surgeons?
Knowledge-focused OngoingThis study looks at whether adding AI-powered images to the surgeon's screen during single-port robotic surgery makes the surgeon's job easier or harder. About 90 urology surgeons and residents will fill out a questionnaire after surgery to rate their mental workload. The goal is…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Tiny study aims to unravel proteinuria mystery in kidney transplant patients
Knowledge-focused OngoingThis observational study follows 25 people with end-stage kidney disease who are receiving a living donor kidney transplant. Researchers want to see how protein in the urine (proteinuria) relates to blood flow in the native kidneys before and after transplant. They also check for…
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can shedding pounds protect kidneys? new study investigates
Knowledge-focused OngoingThis study looks at whether losing weight over two years can improve how the kidneys use oxygen and how the body responds to insulin in people with autosomal dominant polycystic kidney disease (ADPKD) who are overweight. Researchers will use PET scans and insulin tests to measure…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can a Men's cancer support program fit into routine care?
Knowledge-focused OngoingThis study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…
Phase: NA • Sponsor: University College Cork • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New registry tracks how bladder testing device works in real life
Knowledge-focused OngoingThis study is a registry that gathers information from medical records of 500 adults who had a bladder function test using the Glean Urodynamics System. The goal is to see how the system is used in everyday medical practice. No new treatments or procedures are given; it simply co…
Sponsor: Bright Uro • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New study monitors rare calcium disorder to better understand its long-term effects
Knowledge-focused OngoingThis study is for people with autosomal dominant hypocalcemia types 1 or 2, rare genetic conditions that cause low blood calcium. Researchers will collect past and future health data from 95 participants to learn how the disease changes over time. The goal is to better understand…
Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Tiny sensor tracks blood sugar swings in dialysis patients
Knowledge-focused OngoingThis study uses a continuous glucose monitor (a small sensor) to track blood sugar levels in 40 adults with diabetes and end-stage kidney disease who are on dialysis. The goal is to see how glucose changes during and between dialysis sessions over two weeks, and whether those pat…
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Scientists hunt for diabetes genes in large study
Knowledge-focused TerminatedThis study looks at the genetic and molecular factors behind type 2 diabetes, obesity, and related complications like kidney disease. Researchers will collect health information, blood and urine samples, and perform tests like eye exams and ultrasounds from over 2,300 adults, foc…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
New PET scan could reveal which kidney cancer patients respond to immunotherapy
Knowledge-focused OngoingThis study tests a special PET/CT scan that uses a radioactive tracer to see if it can predict how kidney cancer patients will respond to immunotherapy. The trial involves 46 participants with either localized or advanced kidney cancer. Researchers will compare scan results with …
Phase: PHASE2 • Sponsor: James Brugarolas • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Pedaling through dialysis: could High-Intensity cycling shield hearts?
Knowledge-focused OngoingThis study looks at whether high-intensity cycling during hemodialysis can protect the heart from damage that dialysis sometimes causes. Fifteen adults on dialysis will exercise at different intensities during their sessions. Researchers will use echocardiograms to measure heart …
Phase: NA • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Bladder cancer patients monitored years after experimental treatment
Knowledge-focused OngoingThis study follows 6 patients who previously received an experimental treatment (N-803 plus BCG) for non-muscle invasive bladder cancer. Researchers will collect long-term data on survival, cancer recurrence, and test results to see how well the treatment worked over time. No new…
Sponsor: ImmunityBio, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Dialysis fistulas: are they being used two years later?
Knowledge-focused OngoingThis study looks at 1000 people who had a first arteriovenous fistula (AVF) created for dialysis. Researchers want to know how many are actually being used for dialysis two years later, and why some are not. The goal is to understand what prevents these fistulas from being used.
Sponsor: University Paul Sabatier of Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Gene study aims to unlock secrets of kidney disease
Knowledge-focused OngoingThis study looks at 401 people with autosomal dominant polycystic kidney disease (ADPKD) to see how different versions of the PKD1 gene relate to patient traits like age at diagnosis and body size. Researchers are not testing any treatment—they are simply gathering information to…
Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Newborn kidney health under the microscope: AWAKEN 2.0 launches
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how common kidney injury is in newborns in intensive care and what factors increase the risk. Researchers will review medical records of about 4,000 babies from hospitals around the world. The goal is to better understand short- and long-term kidney health, bu…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Bladder cancer survivors share how treatment changes their daily lives
Knowledge-focused OngoingThis study follows 204 people with bladder cancer to see how their quality of life changes after treatment like surgery or radiation. Participants fill out surveys about physical function, pain, fatigue, anxiety, and bladder, bowel, and sexual health. The goal is to understand ho…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Big data study reveals hidden impact of kidney perfusion technique
Knowledge-focused OngoingThis study looks at data from 3,500 kidney transplant patients to understand if a technique called normothermic machine perfusion (NMP) improves outcomes. NMP keeps donated kidneys warm and oxygenated before transplant, but there is no registry field to track it. Researchers will…
Sponsor: Chris Jaynes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Can a 'Learning health System' help thailand tackle its chronic disease crisis?
Knowledge-focused OngoingThis study tests whether a Learning Health System (LHS) can improve care for people with high blood pressure, diabetes, and kidney disease in Thai primary care clinics. The LHS uses electronic health records to help healthcare teams identify patients who need more active manageme…
Phase: NA • Sponsor: Queen Mary University of London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Cancer DNA blood test study halted before it began
Knowledge-focused TerminatedThis study planned to monitor tiny bits of tumor DNA in the blood of people with early breast cancer. Researchers wanted to see how these DNA levels change during treatment and follow-up. The study was withdrawn before any participants were enrolled, so no results are available.
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Can a gene test tell who responds to immunotherapy for bladder cancer?
Knowledge-focused OngoingThis small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New study links blood markers to kidney disease progression in ADPKD
Knowledge-focused OngoingThis study looks at how certain blood chemicals and blood vessel function relate to kidney disease severity in people with early-stage Autosomal Dominant Polycystic Kidney Disease (ADPKD). Researchers will measure homocysteine levels and blood vessel health in 80 participants age…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC